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Abstract 
Tissue engineering has strived to address the need for viable tissue and organ sources to 
treat various diseases, including ischemic disease.  Many of the advances in tissue engineering 
have focused on providing new scaffolds, which may incorporate cells and proteins, to control 
tissue regeneration and growth.  However, further advancement of tissue engineering suffers 
from increasingly complex applications, which require the independent control of the physical 
properties of hydrogel scaffolds.  Also, the need to increase the size of engineered tissues and 
treat ischemic diseases requires new methods to improve blood vessel growth.  Therefore, the 
overall goal of this thesis is to develop advanced strategies for the design of hydrogel scaffolds 
which can tune the physical properties of hydrogels and improve revascularization therapies.   
This thesis describes the development of advanced biomaterials for refined cell culture, 
encapsulation, and neovascularization, including: polymeric cross-linkers which tunes the elastic 
modulus and swelling ratio of hydrogels in a more independent manner (Chapter 2); fibronectin 
or fibronectin fragments in fibrin gels to improve neovascularization (Chapter 3); alginate-sulfate 
to improve the efficacy of VEGF-mediated angiogenesis (Chapter 4); and a multi-functional 
hyperbranched polymer to guide transplanted stem cells to an ischemic tissue (Chapter 5). I 
propose that the biomaterial systems developed in this study should be readily translated into 
various clinical treatments for neovascularization.  Ultimately, the results of this thesis study will 
greatly contribute to expediting the use of tissue engineering technology of various injuries, 
traumas, and diseases.   
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Chapter 1:  Introduction
*
 
1.1 Tissue Engineering 
 In the United States, 112,000 people are currently waiting for organs transplants. In a 
given year only 28,000 will receive organ transplants, and the gap has grown significantly over 
the past 20 years, Figure 1 (1-2).  In addition, many more people suffer from diseases and 
disorders that require tissue transplantations, but they also lack donors.  The disparity between 
patients needing transplants and those receiving transplants is primarily due to a lack of viable 
tissue and organ donors.  Tissue engineering is a multi-disciplinary field, which strives to address 
this disparity by providing readily implantable, manufactured tissues and organs (3).   
 
 
Figure 1:  The year-end statistics for patients in the United States waiting for organ transplants and 
patients receiving transplants from the number of donors.  The statistics were compiled by the US 
Department of Health and Human Services: Organ Procurement Transplant Network (1-2).  
 
                                                 
*
 Portions of this chapter were previously published in: Schmidt JJ, Rowley J, & Kong HJ (2008) Hydrogels used for 
cell-based drug delivery.  J Biomed Mater Res A 87(4):1113-1122. 
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In order to manufacture tissues and organs, tissue engineers attempt to mimic the native 
environment of organs (4).  Organs are complex structures, and are comprised of two main 
components: the cells and the material that surrounds the cells--the extracellular matrix (ECM).  
In an organ, the cells can provide much of the functionality.  For example, one of the functions 
of the pancreas is to regulate the level of glucose in the blood stream.  However, within the 
pancreas specific α-cells and the β-cells secrete the hormones, glucagon or insulin, respectively, 
which controls the glucose levels in the body.  While in an organ, an ECM provides the 
mechanical structure for the organ as a whole and a specific local environment for the cells.  
Interestingly, the local environment provided by the ECM has been shown to control a multitude 
of cell functions.  For example, the differentiation of stem cells can be controlled solely by 
growing them on ECMs of varied stiffness (5-6).  Furthermore, cellular proliferation and 
differentiation is controlled by the number of bonds between stem cells and the ECM (7-8).  
Clearly, the ECM plays a critical role in the development and function of tissues and organs. 
Tissue engineers mimic the native ECM with scaffolds consisting of a number of 
different organic or inorganic materials.  Bioglass®, is one example of a silicon dioxide-based 
ceramic material which has been extensively studied as a scaffold for bone tissue replacement or 
engineering (9).  Bioglass® is an extremely stiff material, allowing it to absorb the stresses 
required of bone tissues.  Furthermore, cells cultured with Bioglass® have shown an 
upregulation of genes, which control of osteogenesis (10).  The bioactivity and biocompatibility 
of Bioglass® in pre-clinical studies has led the FDA to approve Bioglass® for implantation.  
However, the application of materials, like Bioglass®, is often limited in tissue engineering, due 
to the high stiffness and harsh processing conditions of the material (11-12).  Engineering softer 
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tissues such as fat, immature bone, or blood vessels requires more pliable and elastic materials, 
such as hydrogels.   
Hydrogels are highly cross-linked and highly hydrophilic polymer networks, which were 
first used in biological applications as the material for soft contact lenses.  Since then, hydrogels 
have continued to be used for a number of applications, including drug delivery devices and cell 
encapsulation vehicles (13-16).  The recent investigation of hydrogels as in vitro cell culture 
platforms and tissue engineering scaffolds is likely due to the physical and transport properties of 
hydrogels, which are similar to environments within the native body (17).  Hydrogels also have 
mild processing conditions which allow cells to be cultured in 3-dimensions (within hydrogels), 
in addition to 2-dimensions (on top of hydrogels) (18).  The ability of hydrogels to closely mimic 
the in vivo ECM has led to significant academic and industrial research for use of these materials 
as tissue engineering scaffolds.  The subsequent sections will briefly review the current status of 
tissue engineering in terms of the utilization of hydrogel materials, isolated cells, and certain 
bioactive molecules.  One of the major challenges facing tissue engineering, blood vessel 
growth, and the future of tissue engineering will also be discussed 
 
1.2 Overview of Hydrogel Materials in Tissue Engineering 
As a tissue engineering scaffold, hydrogels are required to act as an artificial ECM and 
thus are utilized to organize, protect and direct cells toward a desired function.  The successful 
application of hydrogels as tissue engineering scaffolds relies on many factors, including the type 
of polymers used to form a hydrogel and the control over the physical properties of the hydrogel.  
Both synthetic polymers, such as petroleum-based polymers, and naturally-derived polymers, 
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such as proteins or polysaccharides, have been thoroughly investigated as possible scaffolds for 
tissue engineering   
 
1.2.1 Synthetic hydrogel polymers 
 Synthetic polymers are attractive materials for fabricating tissue engineering scaffolds 
due to their ability to control the physical properties of the polymers.  Physical properties of the 
polymers, such as molecular weight and chemical structure, dictate the mechanical and transport 
properties of the hydrogel scaffolds, and ultimately the success of the tissue engineering 
scaffolds.  A variety of synthetic polymers have been used to form hydrogels for tissue 
engineering, such as, poly(ethylene glycol), poly(acrylic acid), poly(glycerol) and 
poly(hydroxyethyl methacrylate).  These materials have achieved varying degrees of success; 
two of these hydrogel materials are highlighted below. 
Poly(2-hydroxyethyl methacrylate) (pHEMA) is one of the longest studied and most 
utilized synthetic hydrogel materials.  For over 50 years, pHEMA has been used in contact lens 
and drug delivery devices; more recently pHEMA has been used to fabricate tissue engineering 
scaffolds (17, 19).  pHEMA is used in many of these applications, because it does not degrade in 
physiological conditions.  Thus, hydrogels constructed of pHEMA persist throughout biological 
testing.  pHEMA is a biocompatible material because proteins and other cell adhesion materials 
are unable adsorb onto pHEMA hydrogels (20).  pHEMA hydrogels are formed through free-
radical crosslinking, which can be initiated thermally, chemically or through the use of light.  
These varied methods of polymerizing pHEMA hydrogels allow pHEMA hydrogels to form 
various microscructures, specifically as conduits for neural tissue engineering.  The promise of 
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pHEMA hydrogel scaffolds is illustrated by results shown in pre-clinical trials for engineering 
neural and cartilage tissue (21-23). 
Poly(ethylene glycol) (PEG) is the most commonly used synthetic hydrogel material, and 
has received FDA approval for use in a number of biomedical applications.  PEG is a hydrophilic 
material, and PEG hydrogels are resistant to protein adsorption, which significantly improves 
biocompatibility (20, 24).  To form hydrogel scaffolds, PEG molecules are often functionalized 
with acrylate groups at either end, resulting in PEG diacrylate (PEGDA).  The acrylate groups of 
PEGDA cross-link through a free radical polymerization reaction.  Photo-initiators can be used 
to start free radical polymerization and allow patterning of micro-sized features in PEGDA 
scaffolds (25).  The most notable use of PEGDA as a tissue engineering scaffold is the 
encapsulation of islet cells.  PEGDA scaffolds are able to protect exogenous cells from the host 
immune system, but allow the cell secreted insulin to reach the blood stream (26-28).  The 
encapsulation of islets in PEGDA has shown excellent pre-clinical results, and the technology is 
currently in Phase I/II clinical trials (29).  More recently, PEGDA hydrogels have also shown 
promising pre-clinical results as scaffolds for engineering cartilage, fat, bone and neural tissues 
(30-34). 
 
1.2.2 Natural hydrogel polymers 
Natural polymers are attractive hydrogel materials because they are either isolated 
components of the natural ECM, or closely resemble the structure of the natural ECM.  The 
similarities between naturally-derived polymers and the native ECM often leads to excellent 
bioactivity within the scaffolds.  Many naturally-derived polymers have been used to form 
hydrogel scaffolds for tissue engineering; including collagen, fibrin, gelatin, chitosan, alginate, 
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agarose and hyaluronic acid (17).  Specifically, collagen and fibrin (protein based materials) and 
alginate and hyaluronic acid (polysaccharide based materials) will be reviewed further.   
Collagen is the most utilized natural polymer in tissue engineering.  Collagen is the main 
component of the native ECM and makes up nearly a quarter of the total protein in the body.  
Collagen is able to physically cross-link to form gels through a thermal reaction, which allows 
three separate chains of collagen to wrap around each other (35).  The resultant collagen gels are 
excellent scaffolds to support cell culture, and can be degraded by cell secreted metalloproteases.  
Application of collagen gels is often limited due to the poor physical strength of the gels.  
Collagen gels can be reinforced by chemically cross-linking with glutaraldehyde or 
carbodiimides, however this can lead to poor biocompatibility (18).  Collagen scaffolds have 
been successfully used to engineer a number of tissues, including heart valves, blood vessels, 
trachea, small intestine and skin (36-38). 
Fibrin is another protein found within the human body which is closely associated with 
the circulatory system, as fibrin is a critical component to the coagulation of blood.  Isolated 
fibrin has been used in many biomedical applications, such as tissue sealants and surgical 
adhesives (39).  Fibrin gels form through the enzymatic cleavage of fibrinopeptides on 
fibrinogen, which allow the fibrinogen molecules to assemble into fibrin gels.  Fibrin gels readily 
support cell growth and remodeling by cell secreted proteases (40).  Similar to collagen gels, 
fibrin gels are often limited in application due to limited physical strength.  Fibrin scaffolds, 
however, are used to engineer many soft tissues such as muscle, blood vessels, skin and nerves 
(39, 41-42). 
Alginate is a polysaccharide polymer isolated from brown seaweed and structurally 
similar to many polysaccharides located in the native ECM.  Alginate is used in a variety of 
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medical applications because it forms hydrogels under mild conditions and the hydrogels are 
biocompatible.  The structure of the alginate includes a polymer composed of two separate 
polysaccharide blocks of mannuronic acid (M) and guluronic acid (G).  The G blocks are able to 
bind divalent cations, often calcium, and the divalent cations cross-link to form the hydrogel 
(43).  The physical properties of an alginate hydrogel can be controlled using different cations, 
such as barium or magnesium.  Alginate hydrogels have been extensively tested material in 
many pre-clinical and clinical trials for the past few decades, as alginate molecules do not 
associate with many proteins.  The inability of protein to adsorb on alginate hydrogels results in 
the biocompatibility of alginate (17).  One specific use of alginate hydrogels is the encapsulation 
of islet cells in purified alginate hydrogels.  The alginate hydrogel significantly improved the 
therapeutic efficacy of cells by maximizing the viability and minimizing the fibrosis in the 
surrounding tissue (44).  Alginate is easily modified with carbodiimide chemistry, whereby 
molecules possessing primary amines can be linked to the activated acid groups on alginate.  
Utilizing carbodiimide chemistry, recent studies have shown that alginate can be functionalized 
with acrylate and methacrylate groups.  The addition of acrylate groups offers an alternative 
method of cross-linking, via free-radical polymerization.  Free-radical cross-linking of alginate 
can significantly increase the range of stiffness alginate hydrogels can provide (45).  One 
drawback to alginate hydrogel scaffolds is that they lack a cell-controlled degradation 
mechanism, which can limit the expansion of cells within the scaffold (43).  However, alginate 
hydrogels have shown many promising results as tissue engineering scaffolds for bone, cartilage, 
fat and skin tissues (43, 46-48). 
Hyaluronic acid (HA) is also a polysaccharide polymer, but HA is a glycosaminoglycan 
and is found within the ECM of nearly every tissue within the body.  HA forms a hydrogel 
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through covalent cross-linking with hydrazide deriviative or annealing (17).  HA hydrogels have 
low mechanical properties, which can limit its application as a tissue engineering scaffold.  
Recently, HA has been functionalized with acrylate groups, which allows free radical cross-
linking and significantly improves the mechanical properties.  The acrylated HA hydrogels are 
then used to successfully encapsulate cells and culture them over long periods of time (49-50).  
The HA scaffolds undergo degradation and remodeling from cell secreted enzymes, which can 
enhance the efficacy of HA scaffolds.  HA scaffolds have shown promising results in their use as 
engineering scaffolds for skin and wound healing (51-52). 
 
1.2.3  Hydrogel properties 
 Selection of the hydrogel material is important to the success of any hydrogel.  Often the 
selection criteria for hydrogel material is based on the application and the control a material will 
provide over the hydrogel properties.  Control of the hydrogel physical and transport properties 
are crucial to the success of a hydrogel as a scaffold for tissue engineering.   
 Before a hydrogel scaffold is formed, the rheological properties of the pre-gelled solution 
can have a significant effect on cell viability.  Cells are often mixed with pre-gelled polymer 
solutions prior to gel formation.  Mixing cells with highly viscous solutions leads to a significant 
decrease in cell viability because the high shear stress can physically damage cell membranes 
(53-54).  The problems associated with mixing cells and polymer solutions may be tempered by 
engineering the molecular structure of polymer chains to decouple the dependency between the 
viscosity of the pre-gelled polymer solution and the mechanical properties of the gelled polymer.  
For example, one strategy to decrease overall molecular weights of the polymer molecules, while 
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maintaining the number of cross-linking sites, allowed the preparation of hydrogel beads 
presenting high cell viability (55).   
The physical properties of hydrogels have numerous effects on their performance as 
tissue engineering scaffolds.  Specifically, hydrogels need to present the desired mechanical 
stiffness and toughness to structurally protect or support the cells within the tissue engineering 
scaffold.  The stiffness of tissue engineering scaffolds to which cells adhere, regulates cellular 
activities including proliferation, apoptosis and differentiation. 
Various techniques are available to improve the mechanical properties and stabilities of 
hydrogels. The mechanical properties of the gel are commonly controlled by the polymer 
concentration and molar ratio between polymers and cross-linking molecules.  Increasing the 
polymer concentration and shortening the distance between cross-links led to an increase of the 
mechanical stiffness (56).  However, covalently cross-linked hydrogels become more brittle and 
susceptible to failure under mechanical loading exerted by neighboring tissue, as polymers are 
made increasingly stiff through increasing the cross-linking densities (57).  The balance between 
hydrogel stiffness and toughness is illustrated in Figure 1. 
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Figure 2:  The influence of external mechanical loading at implant site on the structural integrity of cell-
encapsulating hydrogels may be mediated with mechanical properties of biomaterials. (a) Stiff 
biomaterials allow the maintenance of the hydrogel structure under compression. (b) Tough hydrogels 
play critical roles in preventing the hydrogel failure by slowing the crack propagation. 
 
In contrast, calcium cross-linked alginate hydrogels allow increases in both stiffness and 
toughness with increased cross-link density, unlike other hydrogels formed from covalent cross-
linking.  The transient nature of the ionic cross-links allow for this dual property control (58).  It 
is likely that this increase in gel toughness accompanied by stiffness increase allows for the 
successful use of these hydrogels during the transplantation of various cells.   
Mechanical properties of hydrogels can also be modulated by reinforcing them with stiff 
inorganic particulates.  Incorporating Bioglass® particles into the hydrogel significantly 
increased the gel stiffness. However, the capabilities of reinforced gels to support cellular 
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viability in vivo remain to be tested (59).  The long-term mechanical stability of hydrogels may 
be further enhanced with semi-interpenetrating network gels and double-network models, which 
significantly improve the gel stiffness and toughness via secondary interactions between 
disparate polymers (60).  However, these approaches commonly alter the pore size of gel 
matrices as represented by the change in the hydrogel swelling ratio.  These changes of pore 
structure significantly influence biomolecular transports into and from hydrogel matrices; as 
discussed below and illustrated in Figure 2.  Therefore, it may be essential to develop a material 
which controls the hydrogel stiffness separately from the pore size of gel matrices for the 
independent control of hydrogel mechanics and transport properties.  
 
 
Figure 3:  Schematic description of the strategies to control transport properties. Optimal diameters of the 
surface pores (a) and bulk pores (b) of cell-encapsulating biomaterials facilitate the biomolecular from 
and into encapsulated cells while minimizing the infiltration of immune system. In contrast, too small 
surface pores (a) and bulk pores (b) inhibits the transports of all essential biological molecules 
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 The success of tissue engineering hydrogels is also determined by their abilities to 
facilitate the influx and efflux of biological molecules to and from cells.  Without careful 
modification of the hydrogel microstructure, hydrogels may act as a physical barrier to limit the 
influx of nutrients and oxygen towards encapsulated cells and prevent the efflux of therapeutic 
molecules and cellular wastes away from the cells.  Typically, the biological transport through 
the hydrogels is regulated on the basis of the surface and bulk pore size of the hydrogel.   
Extensive efforts are being made to control the size of the hydrogel surface pores to 
control the transport of oxygen, nutrients, therapeutic drug molecules and cellular wastes.  
Specifically, the surface pore diameter for a calcium cross-linked alginate hydrogel commonly 
varies from 5 nm to 200 nm (13).  This pore size prevents the diffusion of large molecules, like 
fibrinogen (MW of 3.41x10
5
 g/mol), but allows the diffusion of small molecules, like albumin 
(MW of 6.9x10
4
 g/mol) (61).  This pore size is further controlled by forming polyelectrolyte 
complex layers on the gel surface.  Exposing alginate hydrogels to polycations such as poly-l-
lysine reduces the diffusivity of small molecules, like albumin or hemoglobin (MW of 6.8x10
4
 
g/mol) up to 50%.  The ability of poly-l-lysine to reduce the effective surface pore diameter is 
dependent on the molecular weight of poly-l-lysine and the exposure time.  Decreasing the 
molecular weight of poly-l-lysine molecules and extending exposure time led to a significant 
decrease in the average diameter of pores on the gel surfaces (62).   
The bulk pore size of a hydrogel is controlled by modifying the chemical structure of 
polymers and the cross-linking density of the gel matrix.  The permeability of PEG hydrogels is 
controlled with the molecular weight of PEG molecules, because the difference in molecular 
weights alters the distance between cross-linking points and subsequently the swelling behavior 
and porosity of the gels.  The PEG gels formed from the cross-linking of polyethylene glycol 
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diacrylate (PEGDA) with a molecular weight smaller than 8,000 g/mol presented pores which 
effectively blocked the diffusion of immunoglobulin, albumin, ovalbumin, myoglobin, but not 
vitamin B12 (MW of 1.3kDa).  However, by increasing the molecular weight of the PEGDA to 
20,000 g/mol, the gel becomes permeable to myoglobin (MW of 16.7kDa), which is the size of 
some therapeutic proteins, but the gel remained impermeable to larger proteins, such as 
immunoglobulin (63).  As expected, when PEGDA with molecular weights of 4,000, 8,000 or 
10,000 g/mol were used to encapsulate β-cells, they did not inhibit the diffusion of small 
nutrients into the gel and allowed excellent cell viability (54).  These techniques to control the 
pore structure of hydrogel bulk may also be applicable to other materials, such as poly(vinyl 
alcohol) and poly(HEMA) gels. 
In order for a hydrogel scaffold to act as an artificial ECM, it must be able to organize, 
protect and direct cells towards the desired function.  The successful design of a hydrogel 
scaffold requires careful selection of the material and control of the physical and transport 
properties of the hydrogel.  
 
1.3  Overview of Bioactive Signaling Macromolecules  in Tissue Engineering 
Cells obtain a significant amount of instruction from interactions with the ECM and the 
environment within the ECM.  The native ECM contains many bioactive molecules including 
collagen, laminin, proteoglycans and growth factors (64).  Tissue-engineering scaffolds can be 
designed to influence cells by imitating and interacting with cells through these key bioactive 
molecules from the native ECM.  For example, the cellular receptors bind to specific peptide 
sequences found in many native ECM proteins.  The binding of cells to these peptide sequences 
can control cell function, through subsequent signaling cascades inside of the cells (65).  Also, 
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the binding of soluble growth factors to specific receptors, such Vascular Endothelial Growth 
Factor (VEGF) binding to Vascular Endothelial Growth Factor Receptor (VEGFR) can 
significantly influence cellular function (66).  The regulation of these bioactive molecules, such 
as specific peptide sequences and growth factors can be crucial to the success of tissue 
engineering scaffolds.  
As highlighted earlier, a number of hydrogel materials, such as PEG and alginate prevent 
proteins from adsorbing.  In order to allow for the desired cells to adhere to these hydrogel 
materials, the scaffolds must be chemically functionalized with adhesion proteins.  In some cases 
the full adhesion protein may be functionalized onto the hydrogel scaffold, but in some specific 
cases, only small peptide sequences are necessary for cell adhesion.  The best known cell-
adhesion peptide is arginine-glycine-aspartic acid (RGD), which is a sequence found in many 
ECM proteins including fibronectin, laminin and collagen (67).  Cells bind to the RGD sequence 
with cellular integrin receptors, including αvβ1 and αvβ3.  The modification of alginate 
hydrogels with RGD peptides allows cells to adhere to the alginate scaffold and proliferate.  In 
contrast, cells cultured on alginate hydrogels lacking the RGD peptide showed significant cell 
death (68).  A number of peptides presented from biomaterial scaffolds allow the adhesion of 
various stem and progenitor cells and ultimately the control of cell viability, growth and 
differentiation (69). 
The native ECM is filled with a number of different growth factors that have a profound 
effect on cell function.  Tissue engineering takes advantage of incorporating growth factors into 
hydrogel scaffolds in order to improve control over tissue formation.  For example, Bone 
Morphogenic Proteins (BMP) are a family of growth factors that show significant control over 
the development of bone tissue.  Medtronic has commercialized the use of BMP, specifically 
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BMP-2, in a collagen scaffold to improve bone tissue regeneration in spinal injuries (4).  In 
addition, alginate hydrogels laden with hepatocyte growth factor and fibroblast growth factor-2 
have shown significant improvement in muscle tissue recovery.  Unfortunately, most growth 
factors are plagued by a rapid loss of bioactivity and subsequently limited efficacies (65, 70).  A 
simple method of increasing the bioactivity is to increase the concentration of growth factors, but 
economically this is not feasible.  Binding or tethering growth factors to tissue engineering 
scaffolds is an alternative method to improve the growth factor efficacy.  For example, 
functionalizing VEGF with acrylate allows the growth factor to be covalently linked into a 
PEGDA hydrogel scaffold.  The PEGDA-VEGF scaffold showed significant improvement in the 
ability to stimulate blood vessel formation (71).  Furthermore the covalent linkage or binding of 
a growth factor to a surface can inhibit cellular internalization of growth factors, thus allowing 
the growth factor to persist longer and increase the efficacy.  An alternative method to provide 
and utilize growth factors in a tissue engineering scaffold is to genetically engineer cells to 
secrete the necessary growth factor.  The genetically engineered cells will continually secrete the 
growth factor.  Genetically engineered cells have been utilized in revascularizing and treating 
ischemic tissues.  In a mouse model, treating ischemic tissues with a bolus injection of VEGF 
had limited results.  Introducing VEGF via gene delivery, provided a significant increase in the 
therapeutic efficacy of VEGF and improved the revascularizaton of the ischemic limb (72). 
Overall, the incorporation of bioactive molecules, such as peptides and growth factors 
allows artificial tissue engineering scaffolds to more closely mimic the native ECM.  Ultimately, 
the precise control of these molecules leads to improved cellular function and tissue formation. 
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1.4  Overview of Cells in Tissue Engineering 
Over the past few decades, significant advancements in cell and developmental biology 
have enabled scientists to identify and isolate a number of stem, progenitor and lineage-
committed cell types.  In tissue engineering, these cells are utilized to proliferate, differentiate, 
secrete proteins, and organize into tissues.  Control and proper usage of stem, progenitor and 
lineage-committed cells are crucial to successfully engineering various tissues and organs.   
 Populating a tissue engineering scaffold with cells from the patient is the ideal scenario, 
especially for lineage-committed cells.  Lineage-committed cells comprise the majority of cells 
within a tissue or organ.  The use of lineage-committed cells has been successful in the 
engineering of skin tissues for the treatment of burn victims (4).  However, viable lineage-
committed cells from the patient are often limited and some lineage-committed cells lack the 
ability to proliferate rapidly in vitro (73).  In addition, some tissues and organs are often 
composed of many different cell types and the collection of each distinct lineage-committed cell 
could be exceedingly difficult.   
Stem cells are a subpopulation of cells within the human body that can proliferate or 
differentiate into more specialized cells.  Thus, stem cells are strong candidates to populate tissue 
engineering scaffolds.  Embryonic stem cells (ESC) are some of the most potent stem cells with 
the potential to differentiate into cell types in all three of the germ layers (74).  The potential of 
ESCs have recently been investigated in clinical trials for the treatment of neurological disorders, 
with limited results (75).  In addition, the use of ESCs is often met with ethical concerns from 
segments of the general population.   
Adult stem cells are slightly less potent stem cell populations than ESCs, but are not met 
with the same ethical concerns as ESCs.  Adult stem cells persist in nearly every adult tissue and 
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can differentiate into a variety of cell types, which are often found in the same native tissues of 
the stem cells.  For example, mesenchymal stem cells (MSCs) are located in the bone marrow 
and can differentiate into bone, cartilage and fat cells.  Thus, MSCs have been utilized 
extensively in tissue engineering scaffolds for the treatment of bone defects and have shown 
significant levels of success (4, 76).  Endothelial progenitor cells (EPCs) are also located in the 
bone marrow, but unlike MSCs, EPCs can differentiate into endothelial cells.  The differentiation 
of EPCs into endothelial cells has been successfully applied to engineering of new blood vessels 
and the treatment of ischemic disease (77).  Given the wide variety of cell types, the appropriate 
cell type is often dependent on the end application and cells with viable sources.   
 Stem cells, progenitor cells, and lineage-committed cells are also being exploited for their 
ability to secrete growth factors and cytokines to improve tissue formation.  Specifically, stem 
and progenitor cells secrete a diverse array of growth factors, including vascular endothelial 
growth factor and nerve growth factor, which are used to engineer new blood vessels and 
neurons, respectively (78-79).  Kidney cells and parathyroid cells are examples of lineage-
committed cells, which naturally secrete erythropoietin and parathyroid hormone, respectively.  
These cells are used in tissue constructs necessary for the treatment of anemia and 
hypertheroidism (80-82).  Cells are capable of producing these proteins over an extended time 
period (70).  In addition, cells secrete proteins and cytokines that may not be purified or 
synthesized in a test tube.  This provides the potential to treat diseases and engineer better tissues 
that cannot be obtained with currently available technologies (83).   
Overall, the selection of the optimal cells is dependent on a number of factors; including 
the application and the necessary function of the cells.  However, the use of a variety of cell 
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types, including stem, progenitor and lineage-committed cells in tissue engineering is critical to 
successfully engineering functional tissues and organs.   
 
1.5  Neovascularization in Tissue Engineering 
 In the body, blood vessels supply blood, and ultimately nutrients and oxygen, which are 
vital for the survival of living cells within a tissue.  Blood vessels are located throughout tissues 
and organs, because oxygen and nutrients will only diffuse a few hundred micrometers into the 
tissues.  The growth of new blood vessels (angiogenesis) plays a critical role in growth, tissue 
repair, and wound healing.  Furthermore, nearly all tissue engineering applications strive to 
provide thick, 3-dimensional tissues, which require the transport of oxygen and nutrients to 
maintain viable cells within the engineered tissue.  Tissue engineering would greatly benefit 
from the ability to engineer new blood vessels into constructed tissues.  In addition, engineering 
new blood vessels could treat a number of diseases, which cause a lack of blood flow to a tissue 
or organ (ischemia).  These ischemic diseases lead to significant cell death and tissue necrosis 
(84-85).  
A number of unique methods have been investigated for providing oxygen and nutrients 
to cells with varied effects.  One example is patterning micro-channels into a scaffold that allows 
cells inside of the scaffold to have a source of nutrients (86).  Micro-channels can also be seeded 
with endothelial cells, which aided blood vessel formation (87).  Another example utilizes an 
inductive method, which uses growth factors to cause the native vasculature to invade scaffolds 
(88).  Finally, promising results have been shown by implanting a scaffold inside the body, 
which allow the scaffold to be prevascularized before implantation at the target site, but this may 
lack practicality in translation to the clinic (89). 
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 Overall, blood vessels and angiogenesis are critical components to tissue engineering 
scaffolds and the treatment of many diseases.  New approaches to develop blood vessels are 
crucial to the long-term application of tissue engineering scaffolds, since successful control of 
blood vessel growth will allow the growth of thicker functional engineered tissues and may 
directly provide less invasive treatments for ischemic diseases.   
 
1.6 Conclusions and Project Overview 
Tissue engineering is a complex field of research that strives to manufacture implantable 
organs to meet the needs of patients with serious diseases.  To accomplish this goal, tissue 
engineering may combine hydrogel scaffolds, bioactive molecules and cells to engineer new 
tissues.  Hydrogel-based tissue engineering scaffolds act as an artificial ECM and are fabricated 
from synthetic or naturally-derived materials.  The physical and transport properties of the 
hydrogel scaffold have been shown to have profound impact on the success of the scaffold.  The 
parallel control of the hydrogel structure, processing, and function may lead to further 
improvements in the efficacy of tissue engineering scaffolds.  The interaction between the 
hydrogel scaffold and the cells is similar to the interaction in the native ECM and are dependent 
on the bioactive molecules.  The bioactive molecules, such as peptides or growth factors often 
directly regulate cellular activities of cells within or surrounding the hydrogel scaffolds (6-7).  
Finally, the cells used in tissue engineering are critical to the overall function of new tissues or 
organs.  The cells must provide the specific function of the desired tissue or organ and must be 
readily available.  Despite the significant advances in tissue engineering, many challenges still 
remain, including improving the control of the physical properties of hydrogel scaffolds and 
improving the growth of new blood vessels for the treatment of ischemic disease.   
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Several of the novel strategies I developed in my Ph.D. study, which resolve challenges 
for hydrogel design and neovascularization, will be addressed in the subsequent chapters.  First, 
in Chapter 2, the role of polymer cross-linkers is investigated to control hydrogel properties, 
including hydrogel swelling and hydrogel stiffness.  Chapters 3, 4 and 5 focus on methods for 
improving angiogenesis for the treatment of ischemic disease.  Chapters 3 and 4 discuss the 
effect of fibronectin and alginate-sulfate to improve angiogenesis in a fibrin hydrogel.  Chapter 5 
describes the use of hyper-branched poly(glycerol) to improve the ischemic targeting of 
therapeutic stem cells.  The results from these studies address a few of the challenges facing 
tissue engineering and will be useful for advancing therapies to the clinic.   
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Chapter 2:  Controlling the Dependence of the Elastic Modulus and 
Degree of Swelling with the Flexibility of Polymer Cross-linkers
*
 
2.1.  Introduction 
Hydrogels have been extensively studied for use in various devices and products 
including sensors, actuators, cosmetics, synthetic extracellular matrices, and drug and cell 
carriers (1-8).  These hydrogels are increasingly integrated with various microfabrication 
techniques to assemble pre-defined microstructures and advanced functionalities (9-10).  
Successful use of hydrogels in these applications relies on the ability to control several physical 
properties of hydrogels, such as mechanical rigidity and permeability (11).  For example, 
hydrogels should be rigid enough to maintain their structural integrity in environments subjected 
to mechanical loading or convective flow (12-14).  In addition, hydrogel permeability should be 
reliably tuned to control molecular transport throughout the gel matrix (15-17). 
However, it is often difficult to independently control stiffness and permeability in many 
current hydrogel designs (12).  For instance, hydrogel stiffness is usually increased by increasing 
the number of cross-links, but this leads to a decrease in permeability and molecular diffusivity 
within the hydrogel (18).  Conversely, efforts to increase the hydrogel permeability soften the 
hydrogel.  This inverse dependency between hydrogel stiffness and permeability can therefore 
lead to limited control of hydrogel properties and may limit the effectiveness in their intended 
applications (11).   
                                                 
*
 Portions of this chapter were published in Jeong JH, Schmidt JJ, Cha C, & Kong H (2010) Tuning responsiveness 
and structural integrity of a pH responsive hydrogel using a poly(ethylene glycol) cross-linker. Soft Matter 
6(16):3930-3938. 
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Recently, hydrogels consisting of poly(ethylene glycol) diacrylates (PEGDA) and 
polysaccharides substituted with multiple methacrylic groups demonstrated the ability to increase 
the stiffness of a PEGDA hydrogel without significantly decreasing the swelling ratio (18-19).  
However, it is still difficult to control the swelling ratio of a hydrogel while limiting the change 
of the hydrogel stiffness.  We hypothesized that the chain flexibility of polymeric cross-linkers is 
an important factor to tune the dependency between stiffness and permeability of a hydrogel, 
because of the change in the intramolecular association of the cross-linker.  This hypothesis was 
examined using alginate methacrylates and poly(acrylic acid) methacrylates, as inflexible and 
flexible polymer cross-linkers, respectively.  Alginate with a molecular weight of 100,000 g/mol 
presents larger conformational rigidity than poly(acrylic acid) with an equivalent molecular 
weight, shown by persistence lengths of 32 and 2 nm, respectively (20-21).   
In this study, these polymers were modified by varying the number of methacrylic groups 
to control the number of cross-links in a polyacrylamide hydrogel.  Then, the effect of the 
polymer chain rigidity on the self-association of the polymers was evaluated with pyrene probes 
suspended in the pre-gel solutions (22-23).  The rigidity of the hydrogels incubated in neutral 
media with varying ionic strength was evaluated by measuring the elastic modulus.  In parallel, 
the permeability of the hydrogels was evaluated by measuring the swelling ratio of the 
hydrogels.  Finally, the crucial role of polymer cross-linkers in tuning hydrogel rigidity and 
swelling ratio was demonstrated with microchannels and micro-patterned proteins incorporated 
into a bulk hydrogel and also hydrogels micro-patterned on glass substrates.   
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2.2.  Methods and Materials 
2.2.1.   Synthesis of alginate methacrylates 
Alginate was modified with methacrylic groups using carbodiimide chemistry as 
previously described (18).  In brief, alginate with large fraction of guluronic acid residues 
(LF20/40, molecular weight ~ 100,000 g/mol, FMC Technologies) was dissolved at a 
concentration of 1% in 0.1M (2-(N-morpholino) ethanesulfonic acid) (MES) buffer (Sigma-
Aldrich).  Then, 1-hydroxybenzotriazole (HOBt, Fluka), 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC, Thermo Scientific), and 2-aminoethyl methacrylate (AEMA, Sigma 
Aldrich) were dissolved in the alginate solution and stirred overnight (Figure 1a).  The solution 
was dialyzed, sterilized via filtration, and lyophilized.  The resulting alginate methacrylates were 
reconstituted in deionized water at a concentration of 4 % (w/w).  The degree of substitution of 
methacrylic groups to alginate was determined by titration with NaOH to calculate the number of 
free carboxylate groups (19).   
 
2.2.2. Synthesis of poly(acrylic acid) methacrylates 
Poly(acrylic acid) (PAA, molecular weight ~ 100,000 g/mol, Sigma-Aldrich) was 
modified with methacrylic groups following the same carbodiimide process used to prepare 
alginate methacrylates.  In brief, PAA dissolved in 0.1 M MES buffer at 1 % (w/w) was mixed 
with HOBt, EDC, and AEMA, and they were stirred overnight (Figure 1b).  The DS of 
methacrylic groups to PAA was determined with the titration method described above.  The 
solution was dialyzed, sterilized, and lyophilized.  The PAA methacrylates were reconstituted in 
deionized water to a concentration of 4 % (w/w).   
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2.2.3 Fluorescent analysis of the self-organization between cross-linkers 
The self-organization of polymeric cross-linkers was evaluated using a pyrene probe (24).  
The pyrene (Invitrogen) was dissolved in cyclohexane to prepare a stock solution at a final 
concentration of 6.0 x 10
-6
 M.  The pyrene stock solution was mixed with a solution of the 
polymeric cross-linker with varying polymer concentrations.  Then, the mixture was sonicated 
for 10 minutes to ensure uniform dispersion of pyrene in the polymer solution and further 
incubated overnight to allow the pyrene to preferentially associate with the cross-linkers.  The 
mixture loaded in a quartz cuvette was excited at wavelength of 330 nm and the resulting 
emission spectrum from 350 to 450 nm was obtained using a fluorometer (Fluoromax-4, Jobin 
Ivon).  
 
2.2.4 Preparation of hydrogels  
Hydrogels were prepared through a free-radical cross-linking reaction between 
acrylamide (Sigma-Aldrich) and alginate-methacrylates or PAA-methacrylates.  The acrylamide 
was dissolved in deionized water at a concentration of 7.4 % (w/w).  The cross-linker, alginate 
methacrylates or PAA methacrylates, was added to the acrylamide solution.  The molar ratio 
between the cross-linker and acrylamide was varied from about 0.17 × 10
-3 
to 0.43 × 10
-3
.  A 1 % 
(w/w) ammonium persulfate (APS, Sigma-Aldrich) and 1 % N,N,N,N-
tetramethylethylenediamine (TEMED, Sigma-Aldrich) were added to the pre-gel solution to 
activate the cross-linking reaction.  The mixture was poured between glass plates with a spacer 
of 1 mm thickness.  After one hour, the gel was punched out in a form of a disk with diameter of 
10 mm.  The gel disks were incubated in water until the gel swelling reached equilibrium.   
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2.2.5. Characterization of hydrogel properties 
The hydrogel stiffness was evaluated by measuring the elastic modulus (E) with a 
mechanical tester (MTS Insight, MTS).  At room temperature, the gel disks were compressed at a 
constant rate of 1.0 mm/s, and the resulting stress was recorded by MTS software (Testworks 4).  
The elastic modulus was calculated from the slope of the stress vs. strain curve for the first 10 % 
strain.   
The swelling ratio of the hydrogel (Qm) was measured by weighing hydrogel disks 
swollen to equilibrium and those dried via lyophilization.  The degree of swelling (Q) was 
further calculated using Eq. (1)  
    
  
  
 
 
  
      (1) 
where ρs is the density of water and ρP is the density of polymer.   
The number of elastic cross-links (Nx-link) was calculated from E and Q using Eq. (2), 
assuming that the hydrogel behaves like an elastic network model.(25)   
RT
GQ
N
3/1
linkx        (2) 
where G represents shear modulus, R represents the gas constant (8.314 J mol
-1
 K
-1
) and T 
represents the temperature at which the modulus was measured (25 °C).  Assuming that the 
hydrogel follow an affined network model, G was calculated from the slope of stress vs. - ( λ – λ-
2) curve, where λ is the ratio of the deformed distance to the initial height (26).  
 
2.2.6. Assembly of hydrogels with a microchannel  
A pre-gel solution consisting of acrylamide, polymeric cross-linker, APS, and TEMED 
was mixed with 0.1 % hematoxylin and poured into a polydimethylsiloxane (PDMS) mold, 
which could form a gel cylinder with microchannel at the center.  The cylinder diameter and 
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height were 7 and 1 mm, respectively.  The microchannel diameter was kept constant at 400 μm.  
Following the cross-linking reaction for 1 hour, the resulting gel was removed from the mold and 
incubated in deionized water for 24 hours.  Then, the change in the microchannel diameter was 
quantified using image analysis software (Image J).  
 
2.2.7. Micropatterning of hydrogels on a glass substrate 
Prior to the photolithography step, the glass surface was modified to present methacrylic 
group following a published protocol.(27)  Briefly, slides were cleaned under oxygen plasma for 
1 minute (Diener) and treated in groups of five in a 250 mL glass jar. 500 μL of 3-
acryloxypropyl trimethoxysilane (Gelest) was pipetted around the base of the jar, after which the 
jar was sealed and placed in an oven at 80°C for 4 hours. Slides were rinsed with acetone and 
isopropanol, and dried with using a nitrogen gun.  To obtain approximately 30 μm tall 
microstructures, 9.7 μL of solution was pipetted onto a treated slide, gently covered with an 18 × 
18 mm cover glass, and allowed to spread. Capillary action prevented the solution from 
extending appreciably beyond the boundaries of the cover glass during spreading.  The cover 
glass was brought into contact with a photomask and exposed to a 365 nm wavelength UV light 
at 6.0 mW/cm
2
 for 30 minutes in a mask aligner.  The resulting hydrogels patterned on the glass 
substrates were incubated in deionized water overnight, and the micropatterned hydrogel images 
were captured using an optical microscope.  The change in the size of individual hydrogel pattern 
was quantified using image analysis software (Image J). 
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2.2.8. Micropatterning of proteins on the hydrogel  
Fluorescently labeled bovine serum albumin (BSA) was transferred to a PDMS stamp 
with 250 μm diameter posts.  Then, the PDMS stamp was placed on a glass slide to transfer the 
circular pattern of fluorescent BSA to the glass slide.  Subsequently, polyacrylamide hydrogels 
with varying concentrations of polymer cross-linker were formed on top of the BSA 
micropatterns, following the same procedure as described in Sec. 2.4.  The resulting hydrogel 
was incubated in deionized water overnight, and the area of individual BSA pattern was 
measured using image analysis software (Image J).   
 
2.3. Results 
2.3.1. Synthesis of polymer cross-linkers and fluorescent analysis of their self-association 
Alginate and poly(acrylic acid) (PAA) were modified with methacrylic groups via a 
chemical reaction between carboxylate groups on the polymer and the primary amine group of 2-
aminoethylmethacrylates (Figure 1).  Increasing the molar ratio between the 2-
aminoethylmethacrylates and acid units of the polymers resulted in an increase of the degree of 
substitution of methacrylic groups (DSMA), defined as the percentage of uronic acid units linked 
to the methacrylic groups.  Two degrees of substitution were obtained at 12.5 and 25 % for 
alginate, which was confirmed with titration.  Poly(acrylic acid) was functionalized with an 
equal number of methacrylic groups per polymer chain, as the alginate molecules, which was 
confirmed with titration.  The resulting alginate methacrylates remained soluble in water even 
when half of the alginate uronic acid units were substituted with methacrylic groups.  In contrast, 
the PAA substituted with methacrylic groups at DSMA above 10 % became insoluble in water.   
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Figure 4:  Chemical reaction scheme to prepare (a) alginate methacrylates and PAA methacrylates (b). 
 
The hydrophobic association between the polymers substituted with a varying number of 
methacrylic groups was also examined using the ratio of pyrene emission intensity at 370 nm (I3) 
and that at 360 nm (I1) (Figure 2).  Note that I3/I1 represents the hydrophobic association between 
methacrylic groups linked to the polymer cross-linkers.  I3/I1 of the unmodified alginate or PAA 
solution was independent of polymer concentration.  The I3/I1 of the unmodified polymer 
solution was approximately 0.6, which is characteristic value for the pyrene dispersed in water. 
In contrast, I3/I1 of the polymer cross-linker solution increased as the polymer concentration 
exceeded a critical concentration termed as the critical aggregation concentration (CAC) (Figure 
2b & 2d).  The CAC of alginate methacrylates was higher than the CAC of PAA methacrylates 
by one order of magnitude.  In addition, the CAC for PAA methacrylates was decreased with 
increasing DSMA, while that for alginate methacrylates was independent of the DSMA.   
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Figure 5:  Fluorescent analysis of pyrenes in the pre-gel solutions.  (a) Fluorescence emission spectra of pyrenes 
suspended in aqueous solution of PAA methacrylates.  Polymer concentration was increased from 0.125 () to 0.5 
(), 2.0 () and 4.0 () mg/mL.  DSMA to PAA was kept constant at 5 %.  (b) Dependency of I3/I1, the ratio 
between emission intensity at 370 nm and that at 360 nm, on the concentration of PAA methacylates with DSMA at 5 
() and 10 % ().  (c) Fluorescence emission spectra of pyrenes suspended in alginate methacrylate with DSMA at 
12.5%.  The polymer concentration was increased from 0.0007 () to 0.012 (), 0.19 (), and 3.00 () mg/ml.  (d) 
Dependency of I3/I1 on the concentration of alginate methacylates with DSMA at 12.5 () and 25 % ().   
 
2.3.2. Analysis of elastic modulus and swelling ratio of the hydrogel  
Polyacrylamide hydrogels were prepared via an in situ radical polymerization of 
acrylamide monomers and a cross-linking reaction with either alginate methacrylates or PAA 
methacrylates.  The polyacrylamide did not form a hydrogel without alginate methacrylates or 
PAA methacrylates in the pre-gel solution.  The mixture of polyacrylamide and unmodified 
alginate or PAA also did not form a hydrogel.  Furthermore, in the absence of polyacrylamide in 
(a) (b)
(c) (d)
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the solution, alginate methacrylates and PAA methacrylates did not form a hydrogel within the 
concentration range employed in this study.     
The stiffness of a polyacrylamide hydrogel was evaluated by measuring the elastic 
modulus (E) of the hydrogel.  Increasing the molar ratio between the alginate methacrylates and 
acrylamide (M) from 0.17 to 0.43 × 10
-3
 led to the linear increase of E for the hydrogel (Figure 
3a & Table 1).  Note that the concentrations of the polymer cross-linkers in the pre-gel solutions 
were higher than CAC, characterized in Figure 2.  The dependency of E to M became greater 
with an increase of the DSMA for hydrogels cross-linked by alginate methacrylates.  Therefore, E 
of the hydrogel could be tuned from 27 to 100 kPa.  In contrast, increasing the M for PAA 
methacrylates resulted in a limited increase of E from 9 to 40 kPa.   
The permeability of the hydrogel was evaluated by quantifying the degree of swelling (Q) 
of the hydrogel using Eq. (2).  Increasing DSMA of PAA methacrylates significantly decreased Q 
of the hydrogel from 110 to 40, coupled with increase of M (Figure 3b & Table 1).  In contrast, 
Q of the hydrogel cross-linked by alginate methacrylates was slightly decreased from 45 to 20 
with increasing M.  The inverse dependence of Q on M was minimally changed with increasing 
the DSMA of the alginate methacrylate (Table 1).  The number of elastic cross-links (Nx-link) was 
finally calculated with E and Q of the hydrogel using Eq (3).  Nx-link was linearly increased with 
M and DSMA, and its linear dependency became much larger with use of the alginate 
methacrylates as a cross-linker (Figure 3c). 
Correlating the E of the hydrogel to the Q showed a decrease of Q with increasing E, 
following a power law, but the inverse dependence was smaller with the use of alginate 
methacrylates as a cross-linker (Figure 3d).  The Q of the polyacrylamide hydrogel cross-linked 
by PAA methacrylates rapidly decreased from 110 to 40, while limiting the increase of E from 9 
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to 40 kPa.  In contrast, the Q of the polyacrylamide hydrogel cross-linked by alginate 
methacrylates showed the limited decrease of Q from 45 to 20, while E being increased from 27 
to 100 kPa.   
 
Figure 6:  Analysis of the elastic modulus (E) and the degree of swelling (Q) of the polyacrylamide hydrogel.  (a) 
Dependency of E of the hydrogel on the molar ratio between cross-linker and acrylamide (M). (b) Inverse 
dependency of Q of the hydrogel on M. (c) Dependency of the number of cross-links (Nx-link) and M. (d) Correlation 
of Q to E of the hydrogel.  ■ and ● represent hydrogels cross-linked by PAA methacrylates with DSMA at 5 and 10 
%, respectively.  □ and ○ represent hydrogels cross-linked by alginate methacrylates with DSMA at 12.5 and 25 %, 
respectively.  Data points and error bars represent average of four different values and standard deviation, 
respectively.  The gels were incubated in deionized water for 24 hours before characterization. 
(a) (b)
(c) (d)
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Table 1:  Dependencies of elastic modulus (E) and degree of swelling (Q) of the polyacrylamide hydrogels on M of 
the polymer cross-linker with varied chain inflexibility and DSMA after incubation in deionized water.  
 
2.3.3. Tuning dependencies between elastic modulus and swelling ratio of the hydrogels with 
ionic strength 
Hydrogels cross-linked by alginate methacrylates or PAA methacrylates were incubated 
in aqueous media with varied ionic strength ([I]) from 0 to 170 mM to examine effects of [I] on 
E of the hydrogel.  Increasing [I] of the incubation media led to the decrease of E of the hydrogel 
cross-linked by alginate methacrylates, as M was increased above 0.34 x 10
-3
 (Figure 4a & 
Figure 5a).  In addition, the inverse dependency between E and [I], quantified by fitting it to an 
exponential decay, was strengthened with M (Table 2).  In contrast, [I] minimally influenced E of 
the hydrogel cross-linked by PAA methacrylates, regardless of M (Figure 4b, Figure 5b, and 
Table 2).   
(a) DS (%) Cross-linker Type
Dependency between 
E and [M] (x 10
-3
)
Dependency between 
Q and [M] (x 10
-3
)
5 PAA 41.9 -95.4
10 PAA 96.7 -121.0
12.5 Alg-MA 220.8 -98.1
25 Alg-MA 258.0 -67.2
(b) DS (%) Cross-linker Type
Dependency between 
E and [M] (x 10
-3
)
Dependency between 
Q and [M] (x 10
-3
)
5 PAA 23.4 -51.8
10 PAA 63.7 -55.8
12.5 Alg-MA 166.8 -54.9
25 Alg-MA 191.5 -41.1
(c) DS (%) Cross-linker Type
Dependency between 
E and [M] (x 10
-3
)
Dependency between 
Q and [M] (x 10
-3
)
5 PAA 24.4 -57.3
10 PAA 57.2 -47.2
12.5 Alg-MA 93.7 -39.0
25 Alg-MA 135.5 -30.2
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Figure 7:  Analysis of effects of ionic strength ([I]) and M on elastic modulus (E) of the hydrogel.  (a) Dependency 
of E of the hydrogel cross-linked by alginate methacrylates on [I]. (b) Dependency of E of the hydrogel cross-linked 
by PAA methacrylates on [I].  In these experiments, hydrogels were prepared at varied M of 0.17 (■), 0.26 (●), 0.34 
(□) and 0.43 (○) x 10-3 for each.  DSMA to both alginate and PAA were kept constant at 25 and 10 %, respectively.  
Data points and error bars represent average of four different values and standard deviation, respectively. 
 
 
Figure 8:  Analysis of effects of ionic strength ([I]) and M on elastic modulus (E) of the hydrogel.  (a) Dependency 
of E of the hydrogel cross-linked by alginate methacrylates on [I]. (b) Dependency of E of the hydrogel cross-linked 
by PAA methacrylates on [I].  In these experiments, hydrogels were prepared at varied M of 0.17 (■), 0.26 (●), 0.34 
(□) and 0.43 (○) x 10-3 for each.  DSMA to both alginate and PAA were kept constant at 12.5 and 5 %, respectively.  
Data points and error bars represent average of four different values and standard deviation, respectively. 
The [I] of the incubation media for the hydrogels effected Q and the effect was also 
mediated by the type of polymer cross-linker.  The Q of the hydrogel was inversely dependent of 
[I], as expected.  However, the dependency between Q and [I], quantified by fitting it to an 
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expontential decay, was smaller with the hydrogel cross-linked by alginate methacrylates than 
that cross-linked by PAA methacrylates (Figure 6, Figure 7 and Table 2).     
 
Figure 9:  Analysis of effects of ionic strength ([I]) and M on the degree of swelling (Q) of the hydrogel.  (a) 
Inverse dependency of Q of the hydrogel cross-linked by alginate methacrylates on [I]. (b) Inverse dependency of Q 
of the hydrogel cross-linked by PAA methacrylates on [I].  In these experiments, hydrogels were prepared at varied 
M of 0.17 (■), 0.26 (●), 0.34 (□) and 0.43 (○) x 10-3 for each.  DSMA to both alginate and PAA were kept constant at 
25 and 10 %, respectively.  Data points and error bars represent average of four different values and standard 
deviation, respectively. 
 
Figure 10:  Analysis of effects of ionic strength ([I]) and M on the degree of swelling (Q) of the hydrogel.  (a) 
Inverse dependency of Q of the hydrogel cross-linked by alginate methacrylates on [I]. (b) Inverse dependency of Q 
of the hydrogel cross-linked by PAA methacrylates on [I].  In these experiments, hydrogels were prepared at varied 
M of 0.17 (■), 0.26 (●), 0.34 (□) and 0.43 (○) x 10-3 for each.  DSMA to both alginate and PAA were kept constant at 
12.5 and 5 %.  Data points and error bars represent average of four different values and standard deviation, 
respectively. 
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Table 2: Dependencies of elastic modulus (E) and degree of swelling (Q) of the polyacrylamide hydrogels on ionic 
strength [I] of the hydrogel incubation media.  (a) & (b) Hydrogels cross-linked by PAA methacrylates with DSMA at 
5 & 10 %, respectively.  (c) & (d) Hydrogels cross-linked by alginate methacrylates with DSMA at 12.5 & 25 %. 
 
2.3.4. Microfabrication of hydrogels formed with polymer cross-linkers of varying chain 
inflexibility. 
Hydrogels cross-linked by alginate methacrylates or PAA methacrylates at varying M 
were prepared in various micro-sized configurations to demonstrate the importance of their 
controlled stiffness and permeability in retaining pre-defined microstructure.  First, a hydrogel 
with a 400 μm-diameter microchannel at the center was prepared within a polydimethylsiloxane 
(PDMS) mold (Figure 8a).  Following the incubation in the deionized water, hydrogels prepared 
with alginate methacrylates made minimal change of the microchannel diameter, independent of 
the change in the M from 0.00017 to 0.00043 (Figure 8-I & II & Figure 8c).  In contrast, within 
(a) M(x10
-3
)
Cross-linker 
Type
DS (%)
Dependency 
between E and [I]
Dependency 
between Q and [I]
0.17 PAA 5 19.8 75.2
0.26 PAA 5 25.8 70.5
0.34 PAA 5 8.5 69.7
0.43 PAA 5 9.3 65.0
(b) M(x10
-3
)
Cross-linker 
Type
DS (%)
Dependency 
between E and [I]
Dependency 
between Q and [I]
0.17 PAA 10 22.4 39.8
0.26 PAA 10 -9.8 25.9
0.34 PAA 10 -8.4 24.2
0.43 PAA 10 -20.9 20.0
(c) M(x10
-3
)
Cross-linker 
Type
DS (%)
Dependency 
between E and [I]
Dependency 
between Q and [I]
0.17 Alg-MA 12.5 3.6 23.7
0.26 Alg-MA 12.5 -5.7 16.4
0.34 Alg-MA 12.5 -71.7 11.5
0.43 Alg-MA 12.5 -155.8 8.5
(d) M(x10
-3
)
Cross-linker 
Type
DS (%)
Dependency 
between E and [I]
Dependency 
between Q and [I]
0.17 Alg-MA 25 -12.3 15.0
0.26 Alg-MA 25 -46.1 12.1
0.34 Alg-MA 25 -101.9 9.4
0.43 Alg-MA 25 -156.1 5.3
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the same variation range of M, the hydrogels prepared with PAA methacrylates displayed almost 
two-fold increase of the microchannel diameter with decreasing M from 0.00043 to 0.00017 
(Figure 8b-III & IV and Figure 8c).   
 
 
Figure 11:  Analysis of the change in the diameter of the microchannel introduced in the hydrogel following 
incubation in aqueous media.  (a) Schematic description of the hydrogel containing a microchannel with a diameter 
of 400 µm.  (b) Microphotographs of microchannels in the hydrogel following the incubation in aqueous media for 
24 hours.  Photos I and II display the the microchannel introduced in the hydrogels cross-linked by alginate 
methacrylates at M of 0.00017 and 0.00043 , respectively.  Photos III and IV display the diameter of the 
microchannel in the hydrogels cross-linked by PAA methacrylates at M of 0.00017 and 0.00043, respectively.  
DSMA to both alginate and PAA were kept constant at 12.5 and 5 %, respectively. (c) Quantification of the diameter 
of the microchannel in the hydrogel.  The value and error bar of the each bar represent the average and standard 
deviation of four different samples.  (Scale bar: 100µm) 
Secondly, square hydrogel islands with a length of 500 m were prepared on a glass 
substrate via in situ cross-linking reaction (Figure 9a & b).  The hydrogel islands cross-linked by 
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alginate methacrylates remained intact throughout incubation period (Figure 9c-I & II).  In 
addition, the individual hydrogel islands displayed the minimal geometric change, independent 
of increase in M from 0.00017 to 0.00043.  Therefore, using the alginate methacrylates, we 
could prepare the hydrogel islands with controlled stiffness but comparable surface area.  In 
contrast, the hydrogel islands cross-linked by PAA methacrylates underwent increased swelling 
while decreasing M from 0.00043 to 0.00017.  Ultimately, hydrogel islands prepared at M of 
0.00017 were disintegrated throughout the incubation in the deionized water (Figure 9c-III & 
IV).   
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Figure 12:  Analysis of the swelling of micro-sized hydrogel islands patterned on a glass substrate.  (a) Schematic 
description of the process to prepare hydrogel islands on the glass substrate.  (b) Schematic diagram of the hydrogel 
islands prepared on a glass substrate. (c) Photographs I and II represent the micro-sized islands of the hydrogels 
cross-linked by alginate methacrylates at M of 0.00017 (Photo I) and 0.00043 (Photo II).  Photos III and IV display 
the micro-sized islands of the hydrogel cross-linked by PAA methacrylates at M of 0.00017 and 0.00043.  The 
images of hydrogel islands were captured following incubation in aqueous media overnight (Scale bar: 1 mm) 
 
Finally, fluorescent BSA was printed on the polyacrylamide hydrogel surface into a 
circular pattern with a diameter of 500 m (Fig 10a).  The circular BSA pattern was prepared by 
transferring the proteins stamped on the glass surface to the hydrogel surface via in situ hydrogel 
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formation.  Following incubation in deionized water, the hydrogel cross-linked by alginate 
methacrylates displayed minimal change of the diameter of individual BSA circular patterns, 
independent of change of M from 0.00017 to 0.00043 (Figure 10b-I, 10b-II, & 10c).  In contrast, 
the hydrogels cross-linked by PAA methacrylates displayed significant dependency of the 
diameter of BSA micropatterns, due to the larger expansion of the hydrogel prepared at M of 
0.00017 (Figure 10b-III, 10b-IV, & 10c). 
 
Figure 13:  Analysis of the areal change of the circular pattern of fluorescent BSA immobilized on the hydrogel 
surface following incubation in the aqueous media.  (a) Fluorescent microphotographs of circular protein patterns on 
the hydrogel surface before incubation in the aqueous media.  (b) Fluorescent images of protein islands on the gel 
following the incubation in the aqueous media for 24 hours.  Photos I and II display the minimal difference of the 
diameter of the protein islands on the hydrogels cross-linked by alginate methacrylates at M of 0.00017 and 0.00043.  
Photos III and IV display the significant difference of the area of protein islands on the hydrogels cross-linked by 
PAA methacrylates at M of 0.00017 and 0.00043.  In all images, while dot circles represent the periphery of protein 
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islands.  (Scale bar: 250µm) (c) Quantification of the diameter of the protein patterns on the hydrogel.  The value 
and error bar of the each bar represent the average and standard deviation of ten different samples.   
 
2.4.  Discussion 
The results of this study demonstrate that the dependence between stiffness and 
permeability of a hydrogel can be tuned with polymeric cross-linkers with varied chain 
flexibility.  The more flexible PAA methacrylates displayed a larger number of hydrophobic 
associations in the pre-gel solution than alginate methacrylates.  Using the flexible PAA 
methacrylates as a cross-linker of the polyacrylamide hydrogel resulted in a significant decrease 
in the swelling ratio of the hydrogel with increasing concentration and DS of methacrylic groups 
of PAA methacrylates, while limiting the increase of the elastic modulus.  In contrast, increasing 
the cross-linker concentration and DS of methacrylic groups with rigid alginate methacrylates led 
to a significant increase in the elastic modulus of the hydrogel while limiting the decrease of the 
swelling ratio.  Finally, the polymer cross-linkers with controlled chain flexibility allowed us to 
control the properties and structures of microfabricated hydrogels.   
Earlier studies reported that the persistence length of alginate is ten times longer than that 
of PAA for polymer molecules with similar molecular weights of 100,000 g/mol (20-21).  The 
larger persistence length indicates that alginate is more inflexible than PAA.  This larger 
inflexibility of alginate than PAA originated from the blocks of guluronic acid residues of 
alginate that result in limited rotation between sugar rings, as compared with PAA consisting of 
ethylene units (28).   
The difference in chain flexibility between polymers influenced the hydrophobic 
association between methacrylic groups linked to the polymer, according to pyrene assays.  It is 
common to evaluate the hydrophobic association between polymers with the ratio between 
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emission intensity at 370 nm (I3) and that at 360 nm (I1) (29).  The lower critical aggregation 
concentration of PAA methacrylates than alginate methacrylates implicates that the inflexible 
alginate resists the hydrophobic association more strongly than the PAA.  We propose that the 
hydrophobic association between methacrylic groups results in the methacrylate groups not 
participating in the chemical cross-linking reaction to form a hydrogel, according to previous 
studies performed using fluorescence resonance energy transfer (FRET) (30).  Therefore, the 
effective number of methacrylic groups available to chemical cross-linking reaction is larger 
with alginate methacrylates than PAA methacrylates, at the same overall number of methacrylic 
groups.   
The subsequent analysis of hydrogel stiffness and permeability suggests that the 
relationship between hydrogel properties and inflexibility of the polymer cross-linker should be 
related to the difference of the number of hydrophobically associated domains.  Specifically, the 
larger inverse dependency between Q and E of the hydrogel cross-linked by flexible PAA 
methacrylates indicates that the hydrophobically associated methacrylic groups do not participate 
in the elastic response of the hydrogel but influence Q of the hydrogel.  Conversely, the 
inflexible alginate methacrylates with the smaller number of self-associated domains could 
increase the number of elastic networks in proportional to its concentration and DS of 
methacrylic groups.  The smaller decrease of Q with increasing E of the hydrogel cross-linked by 
alginate methacrylates is attributed to the multiple hydroxyl groups of saccharide units, similar to 
glycosaminoglycan molecules that facilitate water transport in a natural extracellular matrix (19).   
The significant role of self-associated domains on hydrogel properties became more 
evident with the study to examine effects of ionic strength of the hydrogel incubation media on 
the properties.  Interestingly, the hydrogel cross-linked by flexible PAA methacrylates displayed 
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the larger dependency of the Q on the ionic strength, whereas the hydrogel cross-linked by 
inflexible alginate methacrylates exhibited the larger dependency of the E on the ionic strength.  
We interpret that increasing ionic strength of the hydrogel incubation media decrease the 
electrical double layer thickness of the carboxylic acid units of PAA methacrylates, and the 
subsequent decrease of the intra- and intermolecular electrostatic repulsion lead to the stronger 
association between the methacrylic groups of PAA methacrylates.  The resulting compact 
hydrophobic domains likely limited the water entry into the hydrogel, thus resulting in the more 
significant decrease of Q with increasing ionic strength.  In addition, the smaller dependency of 
Q on the ionic strength for the hydrogel cross-linked by alginate methacrylate is attributed to the 
smaller number of hydrophobic domains in the hydrogel.  In addition, the larger inverse 
dependency of E of the hydrogel cross-linked by alginate methacrylates on the ionic strength 
implicates that electrostatic repulsion between the inflexible polymer chains contributes to the 
elastic response of the hydrogel, concerted with the number of cross-links (31).  This effect of 
intermolecular repulsion on the hydrogel stiffness, however, needs to be further investigated in 
future studies.    
Therefore, both these polymer cross-linkers are highly useful in controlling rigidity and 
retaining the geometric shape of various microfabricated hydrogels in a desired manner.  The 
microfabricated features formed in this study are widely used to assemble and functionalize 
hydrogels for molecular or cell carriers, stimulus-responsive actuators, and sensors.  The use of 
alginate methacrylates as a cross-linker is useful in assembling microfabricated hydrogels with 
controlled stiffness, while preserving its micro-sized geometry and the protein patterns on the 
hydrogel.  In contrast, the use of PAA methacrylates as a cross-linker is useful in controlling the 
size of microfeatures introduced into the hydrogels, without significantly altering their stiffness.   
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These interesting roles of chain flexibility of polymer cross-linkers on tuning hydrogel 
properties may be further developed by changing other cross-linker variables, such as the 
molecular weight or the pendant groups.  For example, decreasing the molecular weight of the 
polymer cross-linker will further influence the persistence length of polymer chains and decrease 
the total chain flexibility (32).  Separately, chemical conjugation of polar groups onto the 
polymer cross-linker may counterbalance the hydrophobic association between the flexible 
cross-linkers and facilitate the intermolecular chemical cross-links (33).  Conversely, chemical 
conjugation of hydrophobic groups such as methylene groups, may further amplify the 
hydrophobic association between the polymers (34-35).    
 
2.5.  Conclusion 
In conclusion, this study demonstrates an advanced strategy to control the dependency 
between permeability and stiffness of the hydrogel using polymer cross-linkers with varied chain 
inflexibility.  The flexible PAA methacrylates cross-linker enabled the control of the swelling 
ratio of the hydrogel over a broad range while limiting change of the elastic modulus, because of 
their active hydrophobic association and subsequent aggregation.  In contrast, the inflexible 
alginate methacrylate cross-linker allowed the control of elastic modulus over a broad range 
while limiting the change of the swelling ratio, because of limited hydrophobic association.  Both 
these two polymer cross-linkers were useful to control rigidity and geometry of various 
microfabricated hydrogels in a desired manner.  The results of this study would be highly useful 
to controlling properties of a wide array of hydrogels in the more elaborate manner.  Overall, this 
study will allow one to move one step forward towards the significant improvement of the 
function of hydrogel.   
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Chapter 3:  Modulating VEGF Signaling and Angiogenesis 
with Fibronectin Fragments 
3.1  Introduction: 
Peripheral artery disease (PAD) is one of the most common forms of ischemic disease, 
which affects an estimated 10 million Americans every year (1).  A number of events including 
atherosclerosis, blood clots or severe inflammation results in a lack of blood flow to peripheral 
tissues or organs can cause PAD (2-4).  In severe cases of PAD, surgery is used to restore the 
blood flow to the extremities, but over the past 20 years less invasive techniques have been 
investigated.  Revascularization therapies have shown great promise in their ability to 
circumvent the cause of PAD and restore the blood flow to peripheral tissue (5-7).  This method 
mimics and further regulates many of the complexities of the natural angiogenic process to 
recreate new functional blood vessels.  Angiogenesis is regulated by the orchestration of a 
number of factors including cell recruitment and adhesion, soluble growth factor signaling, and 
extracellular matrix properties.  Through these interactions, endothelial cells are able to sprout, 
form lumens and branch into a new vascular network (8-9).   
One of the critical components for angiogenesis-based revascularization therapies is 
angiogenic growth factors, which stimulate proliferation, migration and differentiation of 
endothelial progenitor and precursor cells.  A variety of angiogenic growth factors have been 
identified including placental-derived growth factor (PDGF), basic fibroblast-like growth factor 
(bFGF) and vascular endothelial growth factor (VEGF) (10-11).  Angiogenic growth factors bind 
to specific receptors on the surface of endothelial cells and subsequently activate the endothelial 
cells through signaling cascades.  For example, VEGF binds to one of the VEGF receptors 
(VEGFR), such as VEGFR-1 or VEGFR-2 (12).  Specifically, the binding of VEGF to VEGFR-2 
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activates internal cell signaling through Mitogen-activated protein kinase (MAPK), c-Src, and 
Phosphoinositide 3-kinase (PI3K).  The stimulation of endothelial cells caused by the binding of 
VEGF to VEGFR-2 plays a critical role in endothelial cell proliferation, migration and formation 
of new blood vessels (13).   
In pro-angiogenic therapies, it is common to administer VEGF systemically through the 
blood stream or locally to a target ischemic tissue.  Both of these approaches suffer from low 
efficacy of VEGF, possibly caused by the quick clearance of VEGF from the body or the poor 
stability of VEGF in vivo (14).  As a result, high dosages of VEGF are repeatedly administered 
for 7 to 10 days to elevate the VEGF level in a target tissue.  However, high dosages of VEGF 
can cause severe side effects, including inflammation and leaky blood vessel formation, resulting 
in immature and dysfunctional vasculature (15).  A variety of devices have been devised to 
improve the efficacy of VEGF, while circumventing repeated high doses of VEGF, including the 
chemical modification of VEGF and encapsulation of VEGF in a broad array of drug carriers 
(e.g., nanoparticles, microparticles, microporous scaffolds, hydrogels).  These techniques have 
exhibited varied degrees of success, and it is essential to further advance the molecular therapies 
for neovascularization (16).   
According to fundamental studies, angiogenesis stimulated by VEGF can be mediated 
with protein molecules from the natural extracellular matrix (ECM), including fibronectin.  
Fibronectin is constituted of many functional groups including domains for cell adhesion, 
heparin/growth factor binding and ECM binding, Figure 1 (17-19).  Fibronectin is therefore 
unique from other ECM proteins, because of its ability to interact with cellular integrins and 
growth factors.  It was previously reported that this dual binding allows fibronectin to play a 
crucial role in mediating the interactions on the surface of endothelial cells.  For example, the 
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activation of the αvβ3 integrin or α4β1synergistically improves the VEGF-VEGFR-2 signaling, 
which would significantly affect angiogenic functions (18, 20-21).  The matrix binding domain 
of fibronectin bridges VEGF to ECM, and subsequently elevates the effective concentration of 
VEGF (22).  These proteins tend to be up-regulated with acute injury and tumor angiogenesis 
(23).  However, there has not been a systematic study on the balance between integrin-binding 
domains and matrix binding domains that would influence VEGF-mediated angiogenesis.    
 
 
Figure 14:  Diagram of fibronectin structure.  This illustrates the different regions of fibronectin including growth 
factor binding (Heparin), cell-binding (Cell) and matrix binding (Fibrin & Collagen) (18). 
 
In this study, we hypothesized that the matrix binding domain of fibronectin is essential 
to enhance angiogenesis attained with co-administration of VEGF and fibronectin.  We 
examined this hypothesis using two fibronectin fragments prepared with recombinant synthesis 
techniques; a fibronectin fragment containing VEGF-binding domain and V3 and 51 
integrin-binding domain and free of matrix binding domains, termed as Fragment #1, and a 
fibronectin fragment containing VEGF-binding domain, 41integrin-binding domain, and 
matrix binding domains, termed as Fragment #2.  The full-length fibronectin was used as a 
positive control.  We first examined effects of VEGF and fibronectin fragments on the extent of 
sprouting, characterized with an in vitro sprouting assay.  In parallel, we evaluated binding 
kinetics of VEGF with artificial cell membrane using surface plasmon resonance (SPR) and the 
phosphorylation level of VEGFR of endothelial cells, in order to address the underlying 
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mechanism.  Finally, the mixture of VEGF and fibronectin derivatives, determined to enhance 
the efficacy of VEGF via in vitro study, was locally administered into an ischemic hindlimb of a 
mouse model to examine its effect on the recovery of blood perfusion.  Overall, the results of this 
study have the potential to greatly improve the quality of angiogenesis-based revascularization 
therapies. 
 
3.2  Methods and Materials  
3.2.1 Sprouting assay 
Primary Human umbilical vein endothelial cells (HUVECs) (Lonza, Walkersville, MD) 
were cultured in endothelial growth media-2 (EGM-2) following the manufacturer’s instruction 
and using the cells before six passages.  Separately, 50 mg of 200 m diameter dextran 
microcarriers (Sigma-Aldrich, St. Louis, MO) were allowed to swell over four hours in 50 mL of 
phosphate buffered saline (PBS) and autoclaved.  The microcarriers were allowed to settle and 
the PBS was exchanged for fresh sterile PBS.  Roughly, 1500 microcarriers were suspended in a 
test tube with 1 x 10
7
 HUVECs, and agitated consistently every 20 minutes, for four hours. The 
cell-adhered microcarriers were placed on tissue culture plates overnight to remove cells not 
adhered to the microcarriers.  The cell-adhered microcarriers were mixed with a solution of 4 
mg/mL fibrin (Sigma-Aldrich) and 4 U/mL aprotinin (Sigma-Aldrich).  In a 96-well plate, the 
fibrinogen and microcarrier solution was mixed with 25 units/mL of human thrombin at a ratio 
of 1:1.  The fibrin hydrogels were formed by incubating the solution at 37°C for 30 minutes.  
Fresh media supplemented with VEGF was placed on top of the hydrogels and exchanged for 
fresh media every two days.  Throughout the cell culture, the sprouting process was monitored 
with a bright-field microscope (Leica DMI 4000).  From the acquired images, the lengths of 
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sprouts were quantified with imaging software (ImageJ).  Furthermore, the number of sprouts 
longer than 90 µm per microcarrier were counted. 
 
3.2.2 Cellular imaging 
After incubation over 8 days, the fibrin gels laden with HUVEC-adhered dextran 
microspheres were washed with PBS, three times.  The washed gels were fixed in formaldehyde 
solution (Sigma-Aldrich) overnight at 4°C.  The formaldehyde solution was removed and the 
gels were washed twice with PBS for one hour to allow the PBS to thoroughly remove the 
formaldehyde in the gel.  The HUVECs adhered to the dextran microspheres were permeabilized 
with 0.5% Triton X-100 (Sigma-Aldrich) and 5% dry milk in PBS for two hours. Intracellular 
actin stress fibers were stained using Oregon Green 514 phalloidin (Invitrogen) and the nuclei 
were stained with 4',6-diamidino-2-phenylindole (DAPI, Invitrogen).  Oregon Green 514 
phalloidin was diluted to 5 U/mL in PBS and DAPI was diluted to 300 nM in PBS before 
staining the cells for four hours.  The cells were subsequently washed with PBS every two to 
four hours for 12 hours and observed with a Leica TCS SP2 confocal microscope. 
 
3.2.3 Fibronectin and fibronectin fragments 
 Fibronectin and fragments of fibronectin were obtained as lyophilized powders (R&D 
Systems).  The powders were reconstituted in PBS and stored at -20°C in aliquots, per the 
manufacturer’s instructions. 
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3.2.4 Assay of VEGFR-2 activation 
HUVECs were cultured, rinsed with PBS and serum-starved for 12 hours prior to 
treatment.  The cells were exposed to 20 ng/mL of VEGF for 10 minutes.  The cells were then 
rinsed with PBS and all the liquid was aspirated from the well.  330 μl of lysis buffer was added 
to the wells, and the mixture of cells and lysis buffer was kept ice cold and agitated for 20 
minutes.  The cell culture plates were scraped, and all liquid was removed from the well and 
sonicated.  The insoluble materials, including cell debris, were removed via centrifugation at 4°C 
for 10 minutes at 8,000 rpm (Eppendorf).  The activation of the cellular VEGFR-2 was finally 
quantified with a Human pVEGFR-2 ELISA kit (R&D Systems), following the manufacturer’s 
instructions. In short, a sandwich-based ELISA was conducted and the absorbance of the 
samples was measured at 450 nm using a plate reader (Biotek Instruments).  The activation of 
the cellular VEGFR-2 was normalized to the total amount of VEGFR-2.  The total amount of 
VEGFR-2 was measured with a Human VEGFR-2 ELISA kit (R&D Systems) in parallel to the 
pVEGFR-2 ELISA kit. 
 
3.2.5 Surface Plasmon Resonance 
A gold sensor chip (GE Healthcare, USA) was modified to present an 11-
mercaptoundecanoic acid (MUA, Aldrich) monolayer by injecting MUA solution into the flow 
cell in a Biacore 3000 (GE Healthcare, USA) for 30 minutes at 25
o
C.  The carboxylic groups of 
the MUA monolayer were then activated by flowing 0.2 M EDC and 0.05 M N-
hydroxysuccinimide (NHS, Aldrich) solutions through the flow cell for seven minutes.  After 
activation, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE, Sigma) was chemically 
linked to the MUA layer by flowing DPPE solution until the response unit was saturated.  The 
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remaining NHS-ester groups on the MUA surface were blocked by injecting 1.0 M ethanolamine 
hydrochloride into the flow cell.  Then, the top layer was built by injecting in a solution 
recombinant human VEGFR-2 for five minutes.  Finally, the mixture of VEGF and fibronectin 
derivatives suspended in PBS at a concentration of 2 µg/ml were injected into the flow cell to 
examine the association and dissociation rates of the VEGF complex with the gold sensor chip 
modified with DPPC and VEGFR-2.  The media flow rate was kept constant at 5.0 μL/min.  The 
kinetic data from SPR sensorgrams were obtained with the assistance of BIA evaluation version 
4.1, where a 1:1 Langmuir binding model was applied to quantify the association and 
dissociation rates (24). 
 
3.2.6 Mouse hindlimb ischemia model 
The hindlimb ischemia surgery was conducted according to protocol approved by the 
Illinois’ Institutional Animal Care and Use Committee.  The animals used were C57BL/6J  
ApoE
-/-
 mice (Jackson Laboratories, ME) that were aged 10 weeks prior to surgery.  The animals 
were anesthetized with a xylazine (10 mg/kg) and ketamine (100 mg/kg) cocktail via intra-
peritoneal injection.  The hair was removed from the lower half of the animal.  A small incision 
was made on the upper thigh of the animal, and the femoral artery and vein were exposed.  The 
femoral artery and vein were ligated, proximal and distal with 5-0 Ethilon sutures (Johnson & 
Johnson, NJ), to stop blood flow to the lower limb.  A 20 µL fibrin gel, encapsulated with 2 µg 
of VEGF and 5 nM of fibronectin or fibronectin fragment, was implanted in between the ligated 
ends of the artery and vein.  The surgical site was closed with 5-0 Ethilon sutures, as well.  The 
blood flow recovery was monitored with Laser Doppler Perfusion Imaging (LDPI; Perimed AB, 
Sweden).  Scans were taken of the ischemic and non-ischemic limbs. 
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The hindlimb tissue was dissected from the animal between the two suture knots which 
marked the surgery-induced ischemic site.  The tissue was fixed in zinc-buffered formalin 
overnight at 4 °C.  The tissues were transferred to 70% ethanol for 12 hours and the 70% ethanol 
was replaced after 6 hours.  The tissues were then processed and embedded in paraffin.  The 
tissues were sectioned, with a thickness of 5 µm and placed on poly-lysine coated glass slides.   
 The paraffin was removed from the slides with histoclear (Fisher Scientific) and the 
sections were rehydrated.  The tissues were stained with primary anti-mouse CD31 antibody 
(1:50) (BD Pharmingen, CA), followed by a biotinylated secondary anti-rat mouse (1:100) (BD 
Pharmingen).  The staining was amplified by with a Tyramide Signal Amplification (TSA) 
Biotin System (Perkin Elmer Life Sciences, MA). The stain was developed with DAB 
chromagen substrate (BD Pharmingen).  The tissues were counterstained with Mayer’s 
Hematoxylin (Sigma-Aldrich) and blued using 0.5% sodium biocarbonate (Sigma-Aldrich).   
 
3.3 Results 
3.3.1 Endothelial sprouting modulated by fibronectin structure  
A three-dimensional (3D) sprouting assay was conducted by culturing HUVECs adhered 
to the surface of dextran microcarriers embedded in a fibrin gel cultured with cell culture media 
supplemented with VEGF, as shown in Figure 2A.  Over eight days, the sprouts of a capillary-
like endothelial lumen were formed from the microcarriers; the length and number of sprouts 
were dependent on the concentration and type of fibronectin derivatives.  No sprouting of cells 
was observed in the fibrin gel embedded in the VEGF-free cell culture media.   
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Figure 15:  A.) Diagram of the sprouting assay, in which HUVECs are seeded on microcarrier beads and embedded 
in a 3D fibrin matrix and cultured for up to 10 days to allow sprouts to form.  B.) Confocal image of cells sprouting, 
the cellular actin (green) and the nuclei (blue) have been fluorescently stained.  Scale is 50μm. 
 
Supplementing VEGF into the cell culture media at a concentration of 10 ng/mL 
increased the number of sprouts formed per bead from 0.3 to 0.8, but only slightly increased the 
length of sprouts from 109 to 127 m.  The incorporation of full-length fibronectin molecules 
further increased the number and length of endothelial sprouts that formed.  Specifically, 
increasing fibronectin concentration from 0 to 5 nM almost doubled the sprout ratio and also 
increased the length of sprouts from 125 to 182 m, shown in Figures 3 and 4.  However, further 
increase of the fibronectin concentration to 90 nM actually decreased the sprouting ratio and the 
length of sprouts.   
A. B.A.
B.
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Figure 16:  Representative images of the influence of the fibronectin concentration (molecular weight of 440kDa) 
on the sprouting of HUVECs with media supplemented with VEGF at 10 ng/mL.  The fibronectin concentrations 
were 0 nM (A.), 0.7 nM (B.) and 5 nM (C.).  (Scale = 110µm) 
 
 
Figure 17:  The influence of the fibronectin concentration (molecular weight of 440kDa) on (A) the number of 
sprouts formed per bead (Sprouting Ratio) and (B) the length of sprouts, measured after 8 days of culture.  VEGF 
concentration was kept constant at 10 ng/mL.  
 
To further investigate the role that fibronectin plays in the angiogenic processes, two 
recombinantly produced fibronectin fragments were incorporated for the sprouting assay at a 
concentration of 5 nM, in addition to VEGF, shown in Figure 5.  One fibronectin fragment, 
Fragment #1, contained the prominent cell binding domain for integrin α5β1 and αvβ3 (FnIII9-10) 
and the heparin/growth factor binding domain.  The second fragment, Fragment #2, contained 
0.7nM 5nM
A. B. C.
0
100
200
300
0.01 0.1 1 10 100
S
p
ro
u
ti
n
g
 L
e
n
g
th
 (
μ
m
)
Fibronectin Conc. (nM)
0
0.5
1
1.5
2
0.01 0.1 1 10 100
S
p
ro
u
ti
n
g
 R
a
ti
o
Fibronectin Conc. (nM)
A. B.
65 
the heparin/growth factor binding and fibrin-binding domains, as well as a cell adhesion domain 
for α4β1 integrin.   
 
Figure 18:   The influence of fibronectin fragments on the number of sprouts formed per bead (Sprouting Ratio) 
(A.) and the length of sprouts (B.), characterized after 8 days of culture.  Both concentrations of fibronectin and 
fibronectin fragments were kept constant at 3nM.  Also, the conditions representing the sprouting assays 
supplemented with no fibronectin (Control) and full-length fibronectin (Fibronectin) are shown (*p<0.05 to Control 
condition)   
 
 Unlike the full-length fibronectin, both Fragment#1 and Fragment #2 did not significantly 
increase the Sprouting Ratio, as compared to the control condition where the cell culture media 
was supplemented only with VEGF.  In contrast, Fragment #2 almost doubled the sprout length 
from 90 to 180 µm, while Fragment #1 minimally increased sprout length over the control.  This 
increase in the sprout length attained with the Fragment #2 was similar to the result from the use 
of full-length fibronectin.   
 
3.3.2 Cellular VEGFR-2 activation modulated by fibronectin structure 
 In parallel, the activation of VEGFR-2 on the surface of HUVECs was examined to 
understand the underlying mechanism by which fibronectin and Fragment #2 increased the 
length of endothelial sprouts.  The VEGFR-2 activation level normalized to the total amount of 
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VEGFR-2 was doubled with exposure to VEGF in the cell culture media.  Incorporation of 
fibronectin or the Fragment #2 further doubled the normalized VEGFR-2 activation level, shown 
in Figure 6.  Overall, culturing HUVECs in the presence of VEGF and Fragment #2 made almost 
four-fold increase of the VEGFR-2 activation level, which was similar to the activation of cells 
cultured with full-length fibronectin.  
 
Figure 19:  Effect of fibronectin on VEGFR-2 activation.  The activation of the VEGFR-2 on HUVECs 
normalized to the total VEGFR-2 expression.  Prior to isolation HUVECs were exposed to VEGF, except in the No 
VEGF control condition.  In addition, cells were cultured in the presence of 3nM of full-length fibronectin 
(Fibronectin) or a fragment of fibronectin containing the growth factor binding domain and the ligand for the α4β1 
integrin (Fragment #2).  (n=8, *p<0.05 to VEGF condition)  
 
  
3.3.3 Surface Plasmon Resonance (SPR) analysis of the VEGF binding kinetics  
The interaction between the mixture of VEGF and fibronectin and the cell surface was 
analyzed with Surface Plasmon Resonance (SPR).  The analysis was conducted on a SPR chip 
functionalized with VEGFR assembled on a lipid bi-layer, an artificial cell membrane, Figure 7.   
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Figure 20:  Formation of the pseudo-cell membrane on the SPR sensor chip.  A.) A schematic of the lipid bi-
layer formed on the surface of the SPR sensor chip, including the inclusion of integrin receptors and the VEGF 
receptor.  B.) The SPR response of depositing the lipid bi-layer on the surface of the lipid bilayer (-●-), the VEGFR 
(-▼-) and Integrin receptors (-■-). 
 
 The lipid bi-layer was successfully deposited on the gold surface of the SPR sensor chip.  
The formation of the lipid bi-layer on the surface of the chip was stable even after challenging 
the integrity at 900 seconds.  The lipid bi-layer coated SPR chip was then used to evaluate the 
binding events of VEGF to the VEGFR on the surface, shown in Figure 8 and Table 1.   
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Figure 21:  SPR responses for the binding of VEGF to the receptor incorporated bi-layer surface.  During an 
association phase (I.) with VEGF flowing across the surface and then a dissociation phase (II.) with a PBS buffer 
flowing across the surface.  VEGF on a surface with VEGFR (-▼-) VEGF with Fragment #2 on a surface without 
VEGFR  (-●-) and VEGF binding to VEGFR in the presence of Fragment #2 (-■-). 
 
Table 3:  The association (ka) and dissociation rate (kd) was quantified by fitting the RU response curve obtained in 
Figure 7, using a Langmuir adsorption model.  The affinity constant (KA) between VEGF and the receptor 
incorporated bi-layer surface.  These were utilized to calculate the total amount of VEGF on the surface after 
dissociation.  
 
 
The SPR analysis shows the association and dissociation of VEGF from VEGFR in the 
bi-layer surface.  The introduction of Fragment #2 decreased the association between VEGF and 
VEGFR, but also decreased the dissociation of the VEGF from VEGFR.  The balance between 
the association and dissociation rates were reflected in the overall increase in the affinity 
(B) Binding process  
Time (s)
0 150 300 450
R
e
s
p
o
n
s
e
 U
n
it
s
 (
R
U
)
0
300
600
900
VEG  with fibro ectin
VEGF with VE R
VEGF with VEGFR
& fibronectin
I. II.
kd                                                
(s
-1
)
ka                                     
(M
-1
s
-1
)
KA                                                    
(M
-1
)
Surface VEGF density 
(number/mm2)
VEGF to blank surface 2.60 x 10
-3
2.31 x 10
5
0.89 x 10
8
2.76 x 10
9
VEGF to VEGFR 1.17 x 10
-3
3.12 x 10
5
2.66 x 10
8
5.36 x 10
9
VEGF with Fragment #2 
to VEGFR 8.93 x 10
-4
2.78 x 10
5
3.11 x 10
8
6.92 x 10
9
69 
constant (KA) when Fragment #2 was present.  Ultimately, the changes in association and 
dissociation lead to an overall increase in final amount of VEGF on the SPR surface.   
 
3.3.4 Treatment of hindlimb ischemia via co-administration of VEGF and fibronectin derivatives 
 A mouse hindlimb ischemia model was used to evaluate the functional angiogenic 
potential of VEGF and fibronectin treatments to restore blood flow to the lower limb.  The 
femoral artery was ligated at the mid-thigh to limit the amount of blood supply to the lower limb, 
shown in Figure 9.   
 
Figure 22:  Scheme of the mouse ischemic hindlimb surgery.  The femoral artery of an anesthetized mouse is 
exposed and ligated, limiting blood supply to the lower limb.  Then treatment is administered to the local surgical 
site and then the site is closed. 
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Fibronectin and Fragment #2 at a concentration of 5 nM were separately mixed with 2 µg 
of VEGF and the mixture was encapsulated into fibrin gels and injected into ischemic hindlimbs 
of mice, as shown in Figure 8.  The recovery of blood perfusion was monitored with Laser 
Doppler Perfusion Imaging (LDPI), shown in Figures 10 and 11.  Ultimately the tissue from the 
hindlimb of the animal was stained for CD31 to illustrate the relative increase in blood vessels, 
shown in Figure 12.   
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Figure 23:  Representative LDPI images of mice after ischemic hindlimb surgery (ischemic limb is the right leg in 
the images) shows the relative intensity blood perfusion imaged after 24 hours (A.).  After 42 days, the ischemic 
limbs that had been treated with a fibrin gel injected to the ischemic site (B.) or a fibrin gel with 2μg of VEGF (B.), 
a fibrin gel with fibronectin with 2μg of VEGF (C.), and a fibrin gel with a fibronectin fragment with 2μg of VEGF 
(D.). 
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Figure 24:  Quantification of the mean blood perfusion in the legs of mice with ischemic hindlimbs.  The perfusion 
ratio (Ratio of perfusion in ischemic to non-ischemic limb was measure in mice treated with a fibrin gel injected to 
the ischemic site (-■-, in A. & B.), a fibrin gel with 2 μg of VEGF (-▲- in A.), a fibrin gel with 5 nM of fibronectin 
with 2 μg of VEGF (-▲- in B.), and a fibrin gel with a fibronectin fragment with 2 μg of VEGF (-●- in B.). (n = 4 
mice, *p < 0.05 with respect to blank fibrin gel)   
 
As shown in Figures 10 and 11, the local injection of VEGF encapsulated in the fibrin gel 
into the ischemic hindlimb significantly enhanced the blood perfusion ratio, defined as the ratio 
of blood perfusion between ischemic hindlimb and intact hindlimb, as compared to the condition 
to inject VEGF-free fibrin gel.  The condition to inject VEGF-free fibrin gel showed the rapid 
increase of the blood perfusion ratio to 0.6 during first 10 days, similar to the condition to inject 
the VEGF-encapsulated fibrin gel.  However, after ten days, the blood perfusion ratio was rather 
decreased to 0.5 through 42 days.  The condition in which the VEGF-encapsulated gel also 
showed no further increase of the blood perfusion ratio after 10 days.  In contrast, the condition 
in which fibronectin or Fragment #2 was incorporated into the VEGF-encapsulated fibrin gel 
exhibited the gradual increase of the blood perfusion ratio to 0.7 through 42 days. 
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Figure 25:  Representative images of histological sections of the hindlimb of mice stained for CD31.  Tissues were 
stained with CD31 antibody and developed using DAB chromagen solution, shown as brown (highlighted with 
arrows).  The tissues were counterstained with hematoxylin, shown in blue.  (A.) represents a blank fibrin gel 
without VEGF nor fibronectin, (B.) represents a fibrin gel encapsulated with 2 μg of VEGF, (C.) represents a fibrin 
gel with 2 μg of VEGF and 5 nM Fragment #2, and (D.) represents a fibrin gel with 2 μg of VEGF and 5 nM 
Fibronectin.  (Scale = 25 µm) 
 
The recovery of blood perfusion from the co-administration of VEGF and fibronectin or 
Fragment #2 was related to the histology in the hindlimb by staining for blood vessels with a 
CD31 antibody.  According to cross-section images of hindlimb acquired after 42 days, local 
injection of VEGF encapsulated in the fibrin gel resulted in an increase in the density of blood 
vessels, as compared to the condition in which the blank fibrin gel was injected, shown in Figure 
12.  Furthermore, co-administration of VEGF and fibronectin or Fragment #2 led to further 
increases in the amount of blood vessels. 
A.
B.
C.
D.
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3.4 Discussion 
The results of this study demonstrate that fibronectin and Fragment #2 are able to 
enhance VEGF-mediated angiogenic efficacy.  Specifically, the fibronectin fragment consisted 
of the VEGF-binding domain, integrin-binding domain, and matrix-binding domain.  This 
fragment of fibronectin could enhance the binding of VEGF with cellular receptors, cellular 
VEGR activation level, and finally increase the length of capillary, according to the in vitro 
study.  In addition, the local administration of fibrin gel encapsulated with VEGF and fibronectin 
fragment containing the matrix-binding domain into an ischemic hindlimb enhanced the recovery 
of blood perfusion through the limb, as compared to the condition to administer the fibrin gel 
encapsulated without VEGF.  The function of the fibronectin fragment containing domains 
binding with VEGF, cellular integrins, and matrix to enhancing VEGF-mediated angiogenesis is 
similar to that of full-length fibronectin.  
An in vitro sprouting assay exhibited that full-length of fibronectin can enhance the 
growth of capillary sprouts depending on its dosage.  The significant decreases of the sprout ratio 
and length at a high fibronectin dosage of 100 nM are attributed to the interference that high 
concentrations of fibronectin can cause in fibrin gel formation (25).  In addition, the sprouting 
assay displayed that the fibronectin fragment #2 significantly increased the length of capillary 
sprouts, which was similar to full-length fibronectin.  We believe the enhanced growth of 
capillary sprouts attained with Fragment #2 may have resulted from an effective increase in the 
concentration of VEGF in the fibrin gel.  This effect could be attributed to the structure of 
Fragment #2, which contains the VEGF-binding domain and a matrix binding domain, which 
could act as a linker to bridge VEGF with the fibrin gel matrix.  The important role of matrix-
binding domain is also addressed by the limited growth of capillary sprouts with use of the 
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fibronectin fragment #1, which lacks the matrix binding domain.  This result shows that in the 
absence of a matrix-binding domain can negate the potential of fibronectin to up-regulate cellular 
V3 integrin expression and subsequent VEGFR activation (21).   
Full-length fibronectin and Fragment #2 were able to modulate the phosphorylation level 
of cellular VEGFR-2 and caused increased binding of VEGF with cellular VEGFR.  Fragment 
#2 of fibronectin was able to enhance the overall binding affinity of VEGF to VEGFR, by 
decreasing the dissociation rate of VEGF from VEGFR.  We propose that the complex between 
the VEGF and the fibronectin derivatives, with a larger size than a single VEGF molecule, would 
display a decrease in entropy.  Therefore, the free energy for dissociation would become smaller 
with the use of fibronectin or fibronectin fragment #2, resulting in the significant increase of the 
number of VEGF bound with cellular VEGFR (26-28).  The enhanced binding affinity of the 
complex of VEGF and fibronectin or fibronectin fragment #2 would elevate the level of VEGFR 
phosphorylation activation level.  The enhanced VEGFR activation level is another mechanism 
by which the full-length of fibronectin and fibronectin fragment #2 would improve the VEGF-
mediated growth of capillary sprouts in a 3D fibrin gel.  However, the potential role of cellular 
41 integrin-binding domain of full-length fibronectin and fibronectin fragment#2 in 
stimulating cellular VEGFR phosphorylation should not be overlooked and should be further 
examined in future studies.   
The in vivo experiment conducted using a mouse model of ischemic hindlimb also 
demonstrated that fibronectin fragment #2 is a beneficial supplement in improving the efficacy 
of VEGF to stimulating angiogenesis process.  In vivo vascularization is dependent on many 
factors, and this process cannot be completely replicated in vitro.  Specifically, ischemia 
resulting from the blockage of blood flow, changes the chemical and mechanical properties of 
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the surrounding tissues may be alternative factors to stimulate or inhibit the angiogenesis, as 
compared with angiogenesis in healthy tissue (29).  Despite this complexity of the in vivo 
environment, the enhanced recovery of blood perfusion and the increase of the number of blood 
vessels highlight the significant effects of fibronectin or the fibronectin fragment #2 on VEGF-
mediated neovascularization.  We believe that VEGF encapsulated in the fibrin gel without 
fibronectin nor fibronectin fragment #2 is readily released from the gel and could stimulates 
some neovascularization, but also inflammation.  In addition, the release of VEGF from fibrin 
would lead to a decrease of the VEGF concentration at the target site, thus limiting the formation 
of mature and functional blood vessels.  Many physiological studies suggest that the VEGF-
mediated signaling needs to be upregulated in a target tissue over multiple days to ensure the 
formation of functional blood vessels (30).  In contrast, the VEGF binding with full-length 
fibronectin or the Fragment #2 would remain in the fibrin gel and have prolonged activity and 
thus would improve the development of mature and functional blood vessels (27).  The increase 
in blood vessel density would lead to the enhanced recovery of blood perfusion in the ischemic 
hindlimb.   
Previously, there have been several studies to examine effects of fibronectin on VEGF-
mediated angiogenesis process using various oligopeptides or fibronectin fragments.  However, 
these studies mostly focused on understanding the role of fibronectin molecules on endothelial 
cell adhesion.  Few studies were made to explore the beneficial effects of fibronectin on 
reconstructing blood vessels and further treating ischemic tissues.  Therefore, this study is 
distinctive from previous studies, because it addresses the role of the matrix binding domain of 
fibronectin or fibronectin derivative in developing functional blood vessels and proposes a 
possible underlying mechanism.   
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3.5. Conclusions 
In conclusion, the results of this study demonstrate that fibronectin or its derivative 
containing domains that can bind with VEGF, cellular integrins, and an extracellular matrix can 
improve the efficacy of VEGF to promote angiogenesis and further treat ischemic tissues via 
revascularization.  We believe that the role of VEGF binding domains and cellular integrin 
domains of fibronectin is greatly diminished in the absence of matrix-binding domain, because it 
may lead to a decreased effective concentration of VEGF.  In addition, the complex of VEGF 
and fibronectin or fibronectin derivative modulates the binding of VEGF-VEGFR and the 
phosphorylation of VEGFR-2.  Improving the efficacy of VEGF in the matrix and leading to 
increased cellular phosphorylation greatly increases the formation of new blood vessels and the 
recovery of blood perfusion.  We expect that the role of fibronectin must be continued with the 
next generation of advanced matrices, which could circumvent softness and fragility of the fibrin 
gel at the implantation site.  However, these findings would be highly useful to improving 
efficacy of neovascularization in treating a variety of tissue defects, severe wounds, and ischemic 
tissues.  In addition, these findings illustrate the role that fibronectin-mediated growth factor 
signaling may be useful in tuning the cellular signaling effects of a wide array of growth factors 
and cytokines.  
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Chapter 4: Regulating Angiogenic Activity with Alginate-Sulfate 
4.1.  Introduction: 
The circulatory system consists of a network of arteries, veins and capillaries tasked with 
moving blood throughout the body.  Blood supplies the cells within the body with essential 
nutrients including oxygen, amino acids, and electrolytes.  The loss or lack of blood supply to the 
cells within a tissue or organ is defined as ischemia and can cause cell malfunction, cell death 
and overall tissue damage (1).  Ischemia can also be the underlying cause or the result of a 
number of diseases, including Ischemic Heart Disease, Peripheral Artery Disease, and Diabetes 
(2-4).  In the treatment of mild cases of ischemic diseases, non-invasive therapies such as 
changes to a patient’s diet, increasing the exercise regimen or certain cholesterol-lowering or 
anti-coagulant drugs may be prescribed.  In more severe cases of ischemic disease, invasive 
(surgical) therapies are needed, such as endarterectomy or grafting/bypasses (5-6).  These 
invasive therapies can possess significant side effects and significant costs.  Over the past 30 
years, less-invasive treatments have been explored to restore or improve blood flow to severely 
ischemic tissues by creating new blood vessels (angiogenesis) around the site of ischemia (7). 
The process of angiogenesis is complex and involves multiple steps which are controlled 
by many different factors.  Angiogenic growth factors are one of the critical components to many 
pro-angiogenic therapies, because they can stimulate many endothelial cell activities critical to 
building microvascular networks (8-9).  Specifically, vascular endothelial growth factor (VEGF) 
is able to bind to one of the VEGF receptors (VEGFR) on the surface of endothelial cells (10).  
The binding of VEGF to VEGFR-2 activates internal cell signaling, which controls endothelial 
cell proliferation, migration, and ultimately the formation of new blood vessels (11).  
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Subsequently, VEGF is able to attract pericytes and smooth muscle cells necessary for the new 
blood vessels to form mature and stable blood vessels (12-13). 
Initially, pro-angiogenic therapies utilized VEGF delivered systemically through the 
blood stream or locally to the target tissue.  However, the quick clearance from the body and 
poor in vivo stability of VEGF led to substandard angiogenesis (14).  To resolve these 
challenges, VEGF was frequently administered at high dosages, which caused severe side effects 
and resulted in dysfunctional vasculature (15).  Therefore, extensive efforts have been made to 
incorporate VEGF into a variety of devices that can release VEGF in a sustained manner and 
subsequently improve the efficacy of VEGF.  These devices include various biodegradable micro 
and nanoparticles, microporous scaffolds, and hydrogels (16-18).  These approaches have 
exhibited varied degrees of success, as compared to the bolus injection of VEGF, and further 
improvements are necessary to ensure the long-term success of tissue engineering-based 
angiogenic therapies (19).  
In the angiogenic process, certain bioactive molecules bind growth factors to stabilize 
and sequester angiogenic growth factors.  Heparin is one of the most important growth factor-
binding molecules; through many different interactions, heparin can modulate many cellular 
processes including angiogenesis.  Specifically, the molecular weight and the negative charge of 
heparin modulate the binding of growth factors and subsequent activation of the growth factor 
receptors (20).  Heparin has been shown to bind VEGF, sequester VEGF in the ECM, and 
minimize the loss of VEGF bioactivity (21-22).  Therefore, the co-administration of VEGF and 
heparin has the potential to improve the recovery of blood perfusion in the ischemic tissue, 
however there are few reports on the potential effect of heparin on revascularization therapies 
and further ischemic tissue treatment.  The use of heparin and other naturally-derived molecules 
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in a clinical setting have been plagued with several issues, such as induced bleeding, immune 
response, mechanical failure, and severe allergic reactions (23-25).   
We hypothesize that the co-administration of VEGF and alginate chemically modified to 
be similar to heparin would significantly improve the efficacy of VEGF in treating ischemic 
tissue via angiogenesis.  To examine this hypothesis, alginate (an FDA approved, anionic 
polysaccharide polymer) was modified with a controlled number of sulfate groups using 
carbodiimide chemistry (26-27).  We then examined the effect that sulfated alginate has on the 
extent of sprouting by utilizing an in vitro angiogenesis assay.  In parallel, we examined the 
effect sulfated alginate has on the binding kinetics of VEGF with cellular receptors using surface 
plasmon resonance (SPR) and the phosphorylation activation of VEGFR-2 of endothelial cells.  
Finally, the sulfated alginate and VEGF were used to enhance the in vivo angiogenesis in the 
ischemic hindlimb of a mouse.  Overall, this research provides a novel bioactive molecule to 
improve the efficacy of VEGF-mediated angiogenesis.  This strategy of molecular design will be 
broadly useful in controlling the efficacy of a wide array of therapeutic proteins for the treatment 
of various diseases. 
 
4.2. Methods and Materials: 
4.2.1 Alginate modification 
Alginate was modified with sulfate groups using carbodiimide chemistry, previously 
described (27).  In brief, alginate with a large fraction of guluronic acid residues (LF20/40, FMC 
Technologies) was dissolved at a concentration of 1% in 0.1 M (2-(N-morpholino) 
ethanesulfonic acid) (MES) buffer (Sigma-Aldrich).  Then, 1-hydroxybenzotriazole (HOBt, 
Fluka), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Thermo Scientific), and 2-
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aminoethyl hydrogen sulfate (Sigma Aldrich) were dissolved in the alginate solution at a molar 
ratio of 2:2:1, respectively, and stirred overnight.  The solution was dialyzed, sterilized via 
filtration, and lyophilized.  The degree of sulfate incorporation was determined with Inductively 
Coupled Plasma (ICP-MS; Perkin Elmer – SciEx ELAN DRC).  The resulting alginate sulfate 
was reconstituted in deionized water at a concentration of 4% (w/w).   
 
4.2.2 Sprouting assay 
 Primary human vein endothelial cells (HUVECs) (Lonza, Walkersville, MD) were 
cultured in endothelial growth media-2 (EGM-2) in accordance with the manufacturer’s 
instructions.  HUVECs, passaged less than six times, were utilized in the sprouting assay, as 
previously described.  In brief, dextran microcarriers (Sigma-Aldrich, St. Louis, MO) were 
swollen over four hours and sterilized by autoclaving.  Roughly 1500 microcarriers were 
suspended in a test tube with 1 x 10
7
 HUVECs, and intermittently agitated for four hours to 
allow the HUVECs to adhere to the microcarriers.  The coated microcarriers were mixed with a 
solution of 4 mg/mL fibrin and 4 U/mL aprotinin.  In a 96-well plate, the fibrinogen and 
microcarrier solution was mixed with 25 units/mL of human thrombin at a ratio of 1:1.  The 
solution was incubated at 37°C for 30 minutes to form a hydrogel, and fresh media supplemented 
with VEGF was placed on top of the hydrogels.  Bright-field images were taken intermittently to 
monitor the sprouting process (Leica DMI 4000) and measurements were taken using image 
processing software (ImageJ).   
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4.2.3 Cellular imaging 
After incubation, the fibrin gels were washed three times in PBS and fixed with a 
formaldehyde solution (Sigma-Aldrich) overnight at 4°C.  The fixed gels were washed twice 
with PBS for one hour and the cells were permeabilized with 0.5% Triton X-100 (Sigma-
Aldrich) and 5% dry milk in PBS for two hours.  The intracellular actin fibers were stained using 
5 U/mL Oregon Green 514 phalloidin (Invitrogen) and the nuclei were stained with 300 nM/mL 
DAPI (Invitrogen) in PBS for four hours.  The cells were subsequently washed with PBS every 
two to four hours for 12 hours and observed with a Leica TCS SP2 confocal microscope. 
 
4.2.4 VEGFR-2 activation 
HUVECs were serum starved for 12 hours prior to treatment.  The cells were exposed to 
20 ng/mL of VEGF for 5 minutes.  The cells were then rinsed with PBS and all the liquid was 
aspirated from the well.  330 μl of lysis buffer was added to the wells and the cells were kept ice 
cold and agitated for 20 minutes.  The surface was scraped and all liquid was removed from the 
well.  The insoluble material was removed via centrifugation at 4°C for 10 minutes (Eppendorf).  
The activation of the cellular VEGFR-2 was quantified with a Human pVEGFR-2 ELISA kit 
(R&D Systems), according to the manufacturer’s instructions. In short, a sandwich-based ELISA 
was conducted and the absorbance of the samples was measured at 450 nm using a plate reader 
(Biotek Instruments).  The activation of the cellular VEGFR-2 was normalized to the total 
amount of VEGFR-2.  The total amount of VEGFR-2 was measured with a Human VEGFR-2 
ELISA kit (R&D Systems) in parallel to the pVEGFR-2 ELISA kit. 
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4.2.5 Surface Plasmon Resonance 
A gold sensor chip (GE Healthcare, USA) was modified to present a 11-
mercaptoundecanoic acid (MUA, Aldrich) monolayer by injecting MUA solution into the flow 
cell in a Biacore 3000 (GE Healthcare, USA) for 30 minutes at 25
o
C.  The carboxylic groups of 
the MUA monolayer were then activated by flowing 0.2 M EDC and 0.05 M N-
hydroxysuccinimide (NHS, Aldrich) solutions through the flow cell for seven minutes.  After 
activation, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE, Sigma) was chemically 
linked to the MUA layer by flowing DPPE solution until the response unit was saturated.  The 
remaining NHS-ester groups on the MUA surface were blocked by injecting 1.0 M ethanolamine 
hydrochloride into the flow cell.  Then, the top layer was built by injecting a solution 
recombinant human VEGFR-2 for five minutes.  Finally, the mixture of VEGF and alginate 
derivatives suspended in PBS at a concentration of 2 µg/ml were injected into the flow cell to 
examine the association and dissociation rates of the VEGF complex with the gold sensor chip 
modified with DPPC and VEGFR-2.  The media flow rate was kept constant at 5.0 μL/min.  The 
kinetic data from SPR sensorgrams were obtained with the assistance of BIA evaluation version 
4.1, where a 1:1 Langmuir binding model was applied to quantify the association and 
dissociation rates (28).  
 
4.2.6 Surgery and analysis of hindlimb ischemia 
The hindlimb ischemia surgery was conducted according to a protocol approved by the 
Illinois’ Institutional Animal Care and Use Committee.  The animals used were C57BL/6J SCID 
mice (Jackson Laboratories, ME) and they were aged 9 weeks prior to surgery.  The animals 
were anesthetized with a xylazine (10 mg/kg) and ketamine (100 mg/kg) cocktail via intra-
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peritoneal injection.  The hair was removed from the lower half of the animal.  A small incision 
was made on the upper thigh of the animal and the femoral artery and vein were exposed.  The 
femoral artery and vein were ligated, proximal and distal, with 5-0 Ethilon sutures (Johnson & 
Johnson, NJ), to stop blood flow to the lower limb.  A 15µL fibrin gel, in which VEGF and 
alginate derivatives were incorporated, was injected between the ligated ends of the artery and 
vein.  The surgical site was closed with 5-0 Ethilon sutures, as well.  The blood flow recovery 
was monitored with Laser Doppler Perfusion Imaging (LDPI; Perimed AB, Sweden) for the 
ischemic and non-ischemic limbs. 
The hindlimb tissue was dissected from the animal between the two suture knots marking 
the surgery-induced ischemic site.  The tissue was fixed in zinc-buffered formalin overnight at 
4°C.  The tissues were transferred to 70% ethanol for 12 hours.  The tissues were processed and 
embedded in paraffin.  The tissues were sectioned (5 µm thick) and placed on poly-lysine coated 
slides.   
 The paraffin was removed from the slides with histoclear (Fisher Scientific) and the 
sections were rehydrated.  The tissues were stained with primary anti-mouse CD31 antibody 
(1:50) (BD Pharmingen, CA), followed by a biotinylated secondary anti-rat mouse (1:100) (BD 
Pharmingen).  The staining was amplified by Tyramide Signal Amplification (TSA) Biotin 
System (Perkin Elmer Life Sciences, MA). The stain was developed with DAB chromagen 
substrate (BD Pharmingen).  The tissues were counterstained with Mayer’s Hematoxylin (Sigma-
Aldrich and blued using 0.5% sodium biocarbonate (Sigma-Aldrich).   
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4.3 Results 
4.3.1 Chemical modification of alginate with sulfate groups 
 Alginate was modified with a number of sulfate groups via chemical reaction between 
carboxylate groups of alginate and primary amine groups of 2-aminoethyl hydrogel sulfate, 
Figure 1.  The degree of substitution of sulfate groups linked to alginate was able to be controlled 
from 1.3 to 13 % by increasing the molar ratio of 2-aminoethyl hydrogen sulfate to the uronic 
acid residue of alginate, as confirmed with Inductively Coupled Plasma-Mass Spectrometry 
(Table 1).   
 
Figure 26:  The chemical structure of alginate and the reaction scheme for the aqueous carbodiimide 
chemistry used to modify alginate.  .   
 
 
Table 4:  The amount of sulfate groups incorporated via carbodiimide chemistry to the alginate polymer 
chain, determined by Inductively Coupled Plasma – Mass Spectrometry.  The sulfate incorporation is 
shown in terms of the degree of substitution (DS) of the uronic acids on the alginate backbone. 
 
 
 
Feed Ratio 
(Sulfate:Alg.)
DS of Sulfates 
on Polymer
0.116 1.3%
0.232 8.9%
0.579 13.3%
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4.3.2 Endothelial sprouting with alginate-sulfate 
The effect of alginate and alginate-sulfate (Degree of substitution (DS) of 5% and 13%) 
on 3-D endothelial sprouting in a fibrin gel was examined, shown in Figures 3 and 4.  The 
alginate or alginate-sulfate was mixed with fibrinogen solution to load them in the fibrin gel.  
The concentration of the alginate-sulfate was varied from at 0.0001 µM to 1.5 µM in the fibrin 
gel and the cell media was supplemented with 15ng/mL of VEGF.   
 
 
Figure 27:  Representative images of HUVECs sprouting in a fibrin gel after 8 days cultured media 
without VEGF (A.), media with 15ng/mL of VEGF (B.), media with 15ng/mL of VEGF and 1 µM 
alginate (C.), and media with 15ng/mL of VEGF and 1 µM alginate-sulfate (Scale = 100 µm) 
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Figure 28:  The influence of alginate-sulfate (DS = 5% (-●-) and DS = 13% (-■-) on the number of 
sprouts formed per bead (Sprouting Ratio) (A.) and the length of sprouts (B.) after 8 days in culture 
supplemented with 15 ng/mL VEGF.  The influence of 1µM alginate or alginate sulfate on the sprouting 
ratio (C.) and the length of sprouts (D.) after 8 days in culture with 15 ng/mL VEGF (*p < 0.05).  
 
 
The incorporation of VEGF at 15 ng/mL stimulated the HUVECs to form endothelial 
lumen sprouts at a ratio of 0.4 sprouts per bead (Figure 2B and Figure 3A).  The absence of 
VEGF in the media resulted in no sprout formation.  The inclusion of unmodified alginate in the 
fibrin matrix with VEGF resulted in a nearly 50% increase in the sprouting ratio over a fibrin gel 
without alginate.  The inclusion of alginate-sulfate (DS of 5%) molecules in the fibrin matrix at a 
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concentration of 1 µM caused an increase in the sprouting ratio from 0.6 to 1.2, but a higher 
degree of substitution (13%) did not alter the sprouting ratio, further (Figure 2D and Figure 3).  .  
Alginate-sulfate (DS of 5% or 13%) also slightly increased the length of sprouts from 115 to 
nearly 165 μm.  Also, decreasing the concentration of the alginate sulfate 100-fold and 10,000-
fold led to significant decrease of the sprouting ratio, to a level similar to a fibrin gel devoid of 
alginate. 
These synergistic increases of the number and length of endothelial lumen sprout 
resulting from the use of VEGF and alginate sulfate was similar to those obtained with use of 
VEGF and heparin.  The heparin was incorporated into the fibrin gel by mixing the heparin with 
fibrin solution, followed by gel formation.  Increasing heparin concentration from 0.0002 to 0.02 
μM resulted in the significant increase of the sprout ratio from 0.2 to 1 sprout per bead (Figure 
4A).  Further increase of the heparin concentration did not increase the sprout ratio.  This 
intermediate heparin concentration was a similar concentration of alginate, which improved the 
sprouting ratio.  In contrast, heparin did not increase the average length of endothelial lumen 
sprouts, whereas the alginate-sulfate in a fibrin gel increased the average lengths (Figure 4B).   
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Figure 29:  A.  The influence of the heparin concentration on the number of sprouts formed per bead 
(Sprouting Ratio) and B. the length of sprouts after eight days in culture.   
 
4.3.3 Cellular VEGFR-2 activation by alginate-sulfate 
 The effect of alginate and alginate-sulfate on VEGFR-2 activation was examined, 
because VEGFR-2 activation has been reported to modulate endothelial function, such as 
proliferation, migration and sprout formation (29).  HUVECs were exposed to a mixture of 
alginate and 20 ng/mL of VEGF to allow VEGF to bind to VEGFRs and cause the internal 
phosphoryl-activation of the receptor.  The activation of VEGFR-2 was normalized to the total 
amount of VEGFR-2, which remained constant.  The normalized amount of VEGFR-2 activation 
showed a slight increase with exposure to alginate and VEGF.  However, HUVECs exposed to 
VEGF and alginate-sulfate showed nearly two-fold increase in VEGFR-2 activation than 
HUVECs exposed to only VEGF (Figure 5). 
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Figure 30:  Activation of VEGFR-2 normalized to the total VEGFR-2 expression.  Prior to isolation 
HUVECs were exposed to 20 ng/mL VEGF, except in the No VEGF control condition.  In addition, cells 
were cultured in the presence of 1 µM of alginate or alginate-sulfate (DS = 5%) (*p<0.05 with respect to 
VEGF condition) 
 
4.3.4 Surface Plasmon Resonance (SPR) analysis of VEGF binding 
 The interaction between the mixture of VEGF and alginate and the cellular VEGFR was 
analyzed by measuring association and dissociation rates with Surface Plasmon Resonance 
(SPR) spectroscopy.  The analysis was conducted on a SPR chip functionalized with VEGFR 
assembled on a lipid bi-layer, an artificial cell membrane, described in Chapter 3.  The 
introduction of unmodified alginate slightly increased the association rate between VEGF and 
VEGFR (Figure 6 and Table 2).  Alginate modified with sulfate groups (DS 13%) significantly 
increased the association rate of the VEGF with VEGFR and decreased the disassociation rate.  
This led to a significant increase in final amount of VEGF on the cell surface.  The balance 
between the changes in the association and disassociation rate constants is shown by the nearly 
double affinity constant (KA) when alginate-sulfate is used (Table 2). 
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Figure 31:  SPR responses for the association and disassociation of VEGF to the VEGF receptor 
incorporated bi-layer surface.  VEGF on a surface with VEGFR (-●-) VEGF with alginate on a surface 
with VEGFR (-▼-) and VEGF with alginate-sulfate binding to VEGFR (-■-). 
 
Table 5:  The association (ka) and dissociation rate (kd) were quantified by fitting the RU response curve 
obtained in Figure 6, using a Langmuir adsorption model.  The affinity constant (KA) between VEGF and 
the receptor incorporated bi-layer surface.  These were utilized to calculate the total amount of VEGF on 
the surface after disassociation. 
 
 
4.3.5 Treatment of ischemic hindlimb with VEGF and alginate-sulfate 
 The effect of alginate and alginate-sulfate on VEGF-mediated angiogenesis was 
evaluated in vivo by injecting the fibrin gel encapsulated with VEGF and alginate derivatives.  
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7.59 x 10-3 209 2.76 x 104
VEGF with Alginate-
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Alginate and alginate-sulfate (DS = 5%) mixed with 2.5 μg of VEGF were encapsulated into a 
fibrin gel, which was then injected into the ischemic hindlimb of mice, shown schematically in 
Chapter 3.  The local injection of VEGF in a fibrin gel led to a recovery of the perfusion ratio 
(ratio of perfusion in ischemic leg to non-ischemic leg) to 0.50 after 28 days, which was 
monitored with Laser Doppler Perfusion Imaging (LDPI) (Figures 7 and 8).  The blood perfusion 
recovery was enhanced to 0.62 with the addition of alginate in the fibrin gel (Figure 7C and 
Figure 8).  The blood perfusion recovery was further increased to 0.75 with the use of VEGF and 
alginate-sulfate in a fibrin gel, after 28 days (Figure 7D and Figure 8). 
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Figure 32:  Representative LDPI images of mice after ischemic hindlimb surgery (ischemic limb is the 
right leg in the images) shows the relative intensity of blood perfusion.  The ischemic leg imaged after 24 
hours (A.) was treated for 28 days with 2.5μg of VEGF in a fibrin gel (B.), fibrin + alginate gel (C.), and 
fibrin + Alg.-SO3 gel (D.).  
A.
B.
D.C.
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Figure 33:  Quantification of the mean blood perfusion in the legs of mice with ischemic 
hindlimbs.  The ischemic leg was treated with 2.5μg of VEGF in a fibrin gel (▲), fibrin + 
alginate gel (●), and fibrin + Alg.-SO3 gel (■).  The perfusion in the ischemic limb was 
normalized to the perfusion in the non-ischemic limb. (n = 4 mice, p < 0.05)   
 
 The improved blood perfusion was further related to the density of blood vessels that 
formed in the hindlimb tissues.  Incorporation of alginate-sulfate into the VEGF-encapsulated 
fibrin gel resulted in the increase of density of blood vessels identified via staining of CD31 
receptors of endothelial (Figure 9).   
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Figure 34:  Representative images of histological section stained for CD31.  Tissues were stained with 
CD31 antibody and developed using a DAB chromagen solution, shown in brown.  The tissues were 
counterstained with hematoxylin, shown in blue.  The ischemic limbs were treated with 2.5 μg of VEGF 
in a fibrin gel (A.), fibrin gel + 1 μM alginate (B.), and fibrin gel + μM alginate-sulfate (C.). (Scale = 25 
μm) 
 
4.4 Discussion 
 The results of this study demonstrated that the use of a sulfated alginate molecule can 
improve angiogenic efficacy.  The alginate-sulfate could enhance the binding of VEGF to the 
VEGFR-2, which would lead to an increase in the VEGFR-2 activation level.  In addition, 
alginate-sulfate significantly increased the number of endothelial lumen sprouts while it slightly 
increased the length of sprouts.  The alginate-sulfate incorporated in the fibrin gel together with 
A.
B. C.
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VEGF was able to significantly increase the level of blood perfusion recovery in an ischemic 
hindlimb as compared to a fibrin gel encapsulated only with VEGF.   
 Through an in vitro sprouting assay, the alginate-sulfate was able to significantly increase 
the number of capillary sprouts that formed per bead and was able to increase the length of 
capillary sprouts, especially with an increasing concentration of alginate-sulfate.  We suggest 
that the increase in angiogenic efficiency of alginate sulfate is caused by the improved 
association between VEGF and VEGFR in the presence of alginate sulfate, according to SPR 
assay.  Alginate substituted with sulfate groups electrostatically associates with VEGF more 
strongly than unmodified alginate molecules (30).  The complex of VEGF and alginate sulfate 
may cause the association with VEGFR more favorably because negatively charged molecules 
are able to bind with VEGF and VEGFR.  In addition, the VEGF complexed with alginate sulfate 
would become bulky and would reduce the entropy for dissociation (31).  Overall, the VEGF and 
VEGFR could associate more favorably in the presence of alginate sulfate, thus resulting in the 
increase of the total number of VEGF associated with cellular receptors.  However, the use of 
alginate-sulfate molecules may also alter the structure of the fibrin matrix, which can be 
addressed in future studies. 
We suggest that the elevated VEGFR-2 activation level attained with alginate-sulfate was 
related to the increased number of bonds between VEGF and VEGFR per cell.  The enhanced 
VEGF signaling should stimulate endothelial cells adhered to a microsphere to grow, migrate 
and finally form endothelial lumen sprouts, as marked with the significant increase of the 
number of sprouts.  In contrast, the insignificant increase of the endothelial lumen may be 
attributed to the uniform distribution of VEGF around endothelial cells on a microsphere.  It is 
known that the concentration gradient of the VEGF is an important factor in extending 
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endothelial lumen (32).  Also, the effects of alginate-sulfate on the VEGFR-2 activation and 
endothelial lumen sprout are similar to the previous effects observed with heparin (31).    
 The in vivo evaluation of the alginate-sulfate using the mouse hindlimb ischemia model 
demonstrated that alginate-sulfate has a significant impact on the angiogenesis process.  Despite 
the complexity of the in vivo environment, the alginate-sulfate was able to significantly increase 
the level of blood perfusion recovery.  The increase in blood perfusion was related to significant 
increase in capillary blood vessels seen in the tissues surrounding the ischemic site.  We believe 
that the increase in blood perfusion is related to the ability of alginate-sulfate to bind VEGF and 
amplify VEGFR activation of host blood vessel-forming endothelial precursor cells.  In addition, 
the function of alginate-sulfate to sequester VEGF in the fibrin gel may be another important 
factor to enhance neovascularization and blood perfusion recovery, because it can increase the 
effectiveness of VEGF in the fibrin gel. 
 The beneficial effects of alginate sulfate on neovascularization and treatment of ischemic 
tissues have not been examined to date.  There have been some studies to control release rate of 
VEGF from a hydrogel supplemented with alginate sulfate (30).  However, there have not been 
studies which report an ability to improve the treatment of ischemic tissues.  In addition, these 
findings show the effect of alginate-sulfate on the interaction between VEGF and cellular 
receptors address another important mechanism by which heparin or heparin-like molecules 
enhance the neovascularization.   
 
4.5. Conclusions 
The results of this study demonstrate that alginate-sulfate can bind to VEGF, improve the 
efficacy of VEGF to stimulating formation of endothelial sprouts, and finally improve the 
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recovery of blood perfusion in the ischemic hindlimb.  This enhanced neovascularization 
attained with alginate sulfate was attributed to the stronger association between VEGF and 
alginate-sulfate, enhanced binding affinity of VEGF with VEGFR, and elevated VEGFR-2 
activation level.  These results demonstrate that alginate sulfate can recapitulate the function of 
heparin or fibronectin to enhancing efficacy of VEGF during homeostasis, healing and 
pathogenesis, but in a more controlled manner via chemical modification.  Overall, the findings 
from this study are broadly applicable to a wide variety of growth factor and cytokine dependent 
therapies and could help to improve these therapies in a clinical setting. 
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Chapter 5: Targeted Cell Delivery for Ischemic Tissue Treatment 
using Bioactive Hyperbranched Poly(glycerol) 
5.1.  Introduction: 
Ischemia in the circulatory system, due to thromboembolism and atherosclerosis, is a 
major cause of strokes and several cardiovascular diseases (1-2).  Critical limb ischemia due to 
injury and chronic disease also leads to limb amputation.  These ischemic diseases are clinically 
treated with drug administration and surgery, which still meet many challenges for the treatment 
on a permanent basis (3-4).  Recently, extensive research has focused on revascularization 
therapies to rebuild the vascular network of the ischemic tissue via angiogenesis, vasculogenesis 
or both angiogenesis and vasculogenesis, to restore blood perfusion of ischemic tissue (1-2, 5-6).  
Various stem and progenitor cells in conjunction with several angiogenic cytokines and growth 
factors are considered promising therapies for revascularization (7-10).  It is common to 
transplant stem and progenitor cells via intracoronary injection, but the therapeutic efficacy of 
the transplanted cells is greatly reduced due to the absence of signals to guide the cells to the 
injured endothelium.  To address these challenges, certain efforts have been made to direct stem 
cells to a target site (11-12).  Although there have been certain impressive results with in vitro 
studies, there are few reports which highlight the efficacy of these stem cell-guidance therapies 
to treat ischemic tissues. 
This study presents the design of a nano-sized cell-guidance molecule and its use in 
ischemic tissue treatment via neovascularization.  The cell-guidance molecule is able to direct 
the intravenously transplanted cells toward the injured endothelium and subsequently improve 
blood perfusion of ischemic tissue.  We hypothesized that hyper-branched poly(glycerol) 
modified with epitopes for binding to both transplanted cells and vascular cell adhesion 
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molecules (VCAM)-1 will guide transplanted cells to the injured endothelium because the 
endothelial injury stimulates endothelial cells to over-express VCAM-1 (13-14).  The 
poly(glycerol) associated with cells will enhance the adhesion of cells to the injured 
endothelium, shown in Figure 1.  Ultimately, the delivered cells would significantly improve 
restoration of blood perfusion in the ischemic tissue because the cells are able to secrete multiple 
angiogenic factors, including vascular endothelial growth factors (VEGF) and basic fibroblast-
like growth factor (bFGF) (15-16). 
This hypothesis was examined using the poly(glycerol) substituted with a varying 
number of octadecyl chains that can associate with lipid molecules of cell membrane and 
oligopeptides that can bind with VCAM of endothelial cells.  The molecular weight of 
poly(glycerol) was also tuned to regulate the binding affinity between cells and poly(glycerol), 
along with the number of octadecyl chains linked to the poly(glycerol).  The resulting 
poly(glycerol) was mixed with mesenchymal stem cells (MSCs) from the adipose tissue of a 
porcine or the bone marrow of a mouse.  MSCs are extensively being studied for 
neovascularization because of their potency to secrete multiple angiogenic growth factors (16).  
The effect of the poly(glycerol) to enhance adhesion of MSCs to injured endothelium was 
examined in vitro to optimize the chemical structure of poly(glycerol).  Also, in vitro studies 
were used to address the underlying mechanism of the binding kinetics between the cells and the 
poly(glycerol), and between the cells coated with poly(glycerol) and the endothelium.  
Furthermore, we transplanted MSCs coated with the bioactive poly(glycerol), optimized via in 
vitro study, into an ischemic hindlimb to demonstrate that the bioactive poly(glycerol) can 
significantly enhance the efficacy of MSCs for recreating blood vessels and restoring blood 
perfusion. 
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Figure 35:  Schematic description of a strategy to guide transplanted EPCs to the injured 
endothelium.  Conventional intracoronary cell transplantation therapy encounters significant loss 
of cells in the target ischemic tissue due to the lack of epitopes to guide transplanted cells to the 
target tissue and adhesion of inflammatory cells (a). In contrast, transplantation of cells 
associated with poly(glycerol) linked with RGD and VHSPNKK peptides are proposed to 
enhance EPC adhesion to the endothelium (b). 
 
5.2. Methods and Materials: 
5.2.1 Poly(glycerol) Synthesis and functionalization 
Hyperbranched poly(glycerol) was synthesized with a one step process previously 
described.  Briefly, the poly(glycerol) synthesis involved the slow addition of glycidol to a basic 
solution of trimethylolpropane (17).  The hyperbranched poly(glycerol) molecules were 
functionalized with octadecyl alkyl chains using a reaction with octadecylbromide and the 
hydroxyl groups of the poly(glycerol).  Furthermore, VCAM targeting peptides with the 
sequence of NH2-CG4VHSPNKKASSKY-COOH were conjugated to the hyperbranched 
poly(glycerol) by first functionalizing the poly(glycerol) with certain amounts of acrylate groups 
(18).  Utilizing a Michael-type addition reaction, the cysteine on the peptide was reacted with the 
poly(glycerol) acrylate at a 1:1 molar ratio of acrylates to peptides.  Subsequently, the 
poly(glycerol) solution was dialyzed, sterilized via filtration, and lyophilized.  The bioactive 
poly(glycerol) was further modified with fluorescein by a reaction with lysine residues on the 
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peptide with succinimidyl fluorescein (Invitrogen) and imaged with a fluorescent microscope 
(Leica DMI 4000). 
 
5.2.2 Surface Plasmon Resonance 
A gold sensor chip (GE Healthcare, USA) was modified to present a 11-
mercaptoundecanoic acid (MUA, Sigma-Aldrich) monolayer by injecting MUA solution into the 
flow cell in a Biacore 3000 (GE Healthcare, USA) for 30 minutes at 25
o
C.  The carboxylic 
groups of the MUA monolayer were then activated by flowing 0.2 M EDC and 0.05 M N-
hydroxysuccinimide (NHS, Sigma-Aldrich) solutions through the flow cell for seven minutes.  
After activation, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE, Sigma-Aldrich) 
was chemically linked to the MUA layer by flowing DPPE solution until the response unit was 
saturated.  The remaining NHS-ester groups on the MUA surface were blocked by injecting 1.0 
M ethanolamine hydrochloride into the flow cell.  Then, the top layer was built by injecting in a 
solution recombinant human VCAM for five minutes.  Cells were associated with poly(glycerol) 
by mixing the 1 x 10
7
 cells with 75 µL of polymer solution (2.0 mg/mL).  The cells were 
concentrated via centrifugation and washed with a saline solution.  A solution of 1 x 10
6
 
cells/mL was injected at a flow rate of 5.0 μl/min over the sensor chip.  The kinetic data from 
SPR sensorgrams were obtained with the assistance of BIA evaluation version 4.1, where a 1:1 
Langmuir binding model was applied to quantify the association and dissociation rates (19). 
 
5.2.3 Rolling cell, flow chamber assay 
Endothelial cells (ATCC) were culture on collagen coated glass slides until confluent.  
Cells were treated with 0.03 µg/mL of tumor necrosis factor – alpha (TNF-α) for four hours 
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activating the cells to express VCAM (20).  The cell coated glass slides were then assembled as 
the bottom of the laminar flow chamber.  Mouse MSCs were associated with poly(glycerol) by 
mixing the 1 x 10
7
 cells with 75 µL of polymer solution (2.0 mg/mL).  The cells were 
concentrated via centrifugation and washed with a saline solution.  A solution of 1 x 10
6
 
cells/mL was injected into a custom-made flow chamber via a 30 mL syringe mounted on a 
syringe pump.  The cell solution was passed over the confluent, VCAM-expressing, endothelial 
cells in the flow chamber and were imaged via an inverted microscope (Leica DMI 4000). 
 
5.2.4  Murine hindlimb ischemia model 
The hindlimb ischemia surgery was conducted according to protocol approved by the 
Illinois’ Institutional Animal Care and Use Committee.  The animals used were C57BL/6J SCID 
mice (Jackson Laboratories, ME) that were aged 10 weeks prior to surgery.  The animals were 
anesthetized with a xylazine (10 mg/kg) and ketamine (100 mg/kg) cocktail via intra-peritoneal 
injection.  The hair was removed from the lower half of the animal.  A small incision was made 
on the upper thigh of the animal and the femoral artery and vein were exposed.  The femoral 
artery and vein were ligated, proximal and distal with 5-0 Ethilon sutures (Johnson & Johnson, 
NJ), to stop blood flow to the lower limb.  The surgical site was closed with 5-0 Ethilon sutures, 
as well.  Then 60,000 porcine adipose-derived stem cells were injected through the tail vein of 
the animal.   
For imaging of cells delivered intravenously, cells were labeled with a fluorescent 
infrared cell membrane dye (CellVue NIR815, LI-COR Biosciences) according to the 
manufacturer’s instructions.  Subsequently, the cells were delivered via tail vein injection, as 
described previously.  After 16 hours, the tissues were recovered from the animal and fixed in 
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4% paraformaldehyde (Sigma-Aldrich) for 24 hours.  The cells and tissues were then imaged 
using an IR imaging system (excitation of 785 nm) (Odyssey Imager, LI-COR Biosciences).   
The blood flow recovery was monitored with Laser Doppler Perfusion Imaging (LDPI; 
Perimed AB, Sweden).  Scans were taken of the ischemic and non-ischemic limbs.  For 
histology, the hindlimb tissue was dissected from the animal between the two suture knots 
marking the surgery-induced ischemic site.  The tissue was fixed in zinc-buffered formalin 
overnight at 4 degrees Celsius.  The tissues were transferred to 70% ethanol for 12 hours.  The 
tissues were processed and embedded in paraffin.  The tissues were sectioned (5 µm thick) and 
placed on poly-lysine coated slides. 
The paraffin was removed from the slides with histoclear (Fisher Scientific) and the 
sections were rehydrated.  The tissues were stained with primary anti-mouse CD31 antibody 
(1:50) (BD Pharmingen, CA), followed by a biotinylated secondary anti-rat mouse (1:100) (BD 
Pharmingen).  The staining was amplified by Tyramide Signal Amplification (TSA) Biotin 
System (Perkin Elmer Life Sciences, MA). The stain was developed with DAB chromagen 
substrate (BD Pharmingen).  The tissues were counterstained with Mayer’s Hematoxylin (Sigma-
Aldrich and blued using 0.5% sodium biocarbonate (Sigma-Aldrich). 
 
5.3 Results 
5.3.1. Coating of cells with poly(glycerol) substituted with octadecyl chains  
Poly(glycerol) substituted with octadecyl chains was prepared by chemical reaction 
between octadecylbromide and hydroxyl groups of poly(glycerol) with a molecular weight of 
either 60,000 or 150,000 g/mol (Figure 1A).  The presence of octadecyl chains on the 
poly(glycerol) was confirmed with 1H NMR (Figure 1B).  The degree of substitution of 
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octadecyl (C18) chains linked to poly(glycerol) was kept constant at 10 per poly(glycerol).  The 
resulting poly(glycerol)-g-C18 remained soluble in water. 
 
Figure 36:  Synthesis of poly(glycerol)-g-C18.  (A.) Chemical reaction scheme to prepare poly(glycerol)-g-C18.  
(B.) 1H NMR of poly(glycerol) with alkyl chains. 
 
The capability of poly(glycerol)-g-C18 to associate with cells was evaluated by 
measuring an association rate (ka), a dissociation rate (kd), and the number of poly(glycerol)s 
adhered to a lipid bilayer, which was used as a model cell membrane, using SPR.  The octadecyl 
chains conjugated to the poly(glycerol) significantly increased the association rate and decreased 
the dissociation rate (Figure 3A & Table 1).  The effect of the poly(glycerol)-g-C18 molecular 
weight on the adhesion properties was further investigated.  Increasing the molecular weight 
(MW) of poly(glycerol) from 60 kDa to 150 kDa led to a two-fold increase of the association 
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rate, and a decrease of the dissociation rate by 67 %.  Therefore, the higher MW poly(glycerol) 
displayed a two-fold higher association constant (KA) quantified with the ratio between the 
association rate and the dissociation rate.  Finally, chemical modification of the low MW 
poly(glycerol)-g-C18 led to a two-fold increase of the number of poly(glycerol) associated with 
the lipid bilayer, as compared to the unmodified poly(glycerol) (Table 1).  In contrast, the high 
MW poly(glycerol)-g-C18 displayed the ten-fold increase of the poly(glycerol) density adhered 
to the lipid bilayer, as compared to the unmodified poly(glycerol).  Furthermore, the high MW 
poly(glycerol)-g-C18 displayed stronger association with mesenchymal stem cells than the low 
MW poly(glycerol)-g-C18, as confirmed with the brighter fluorescence from the polyglcerol 
associated with cells (Figured 3B). 
We further examined the underlying mechanism by which octadecyl chains improve the 
adhesion of poly(glycerol)s to the artificial cell membrane by quantifying the changes of 
enthalpy, entropy, and Gibbs free energy.  For the high MW poly(glycerol)-g-C18, the KA was 
decreased with increasing temperature, fitted to a linear regression between 1/ln(KA) and 
1000/Temperature (Figure 3C-D & Table 2).  The change of Gibbs free energy (G) calculated 
from –RT ln (KA) reached around -11 J for the high MW poly(glycerol)-g-C18 and the change of 
enthalpy and change of entropy were negative values.  In contrast, the low MW poly(glycerol)-g-
C18 displayed independence between KA and temperature, and the resulting G was almost zero. 
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Figure 37:  (A.) SPR analysis of the binding of poly(glycerol)-g-C18 of 6,000 (▼) and 150,000 g/mol (■). (B.) 
Fluorescence images of the cells associated with poly(glycerol)-g-C18 conjugated with fluoroscein.  (C.) SPR 
analysis of the binding of poly(glycerol)-g-C18 at varied temperature of  25 (■), 31 (▼), and 37 °C (●). (D.) 
Dependence of KD on temperature. 
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Table 6:  Quantitative analysis of the association rate (ka), dissociation rate (kd), affinity constant (KA), and number 
of poly(glycerol)-g-C18 of varying molecular weights adhered to the lipid bilayer. 
 
Table 7:  Quantified analysis of the effect of temperature on the association rate (ka), dissociation rate (kd), affinity 
constant (KA), and changes of enthalpy (H), entropy (S), and Gibbs free energy (G) of poly(glycerol)-g-C18 towards 
the lipid bilayer 
 
 
5.3.2.  Modification of poly(glycerol)-g-C18 with VCAM-targeting oligopeptides 
The poly(glycerol)-g-C18 was further modified with VCAM-binding peptides with the 
sequence of VHSPNKK.  The hydroxyl groups of poly(glycerol)-g-C18 were first modified with 
methacrylic groups to subsequently react them with thiol groups attached to VHSPNKK peptides 
via Michael reaction (Figure 4A).  As expected, the poly(glycerol) modified with VHSPNKK 
peptides displayed the capability to associate with VCAM molecules placed on a lipid layer on 
the SPR chip (Figure 4B).  The unmodified poly(glycerol)-g-C18 displayed minimal adhesion to 
the VCAM-coated substrate.  The conjugation of the oligopeptides to the poly(glycerol) 
increased the maximum response unit, which was related to the number of poly(glycerol) 
MW of 
polyglycerol 
(g/mol) 
Conc. 
(mg/mL)
Response   
unit (ΔRU) 
kd  (1/s) ka  (1/Ms) KD (M) KA (1/M) 
Surface 
density 
(number/mm2) 
150,000
0.05 
(0.50 µM) 
1900 3.98 × 10-4 3.03 × 104 1.32 × 10-8 7.6 × 107 
11.4 × 109
 (PG) 
11.8 × 1010
(Alkyl)
60,000
0.05
(8.33 µM)
277 9.69 × 10-4 1.70 × 103 5.69 × 10-7 1.76 × 106 
27.8 × 109
 (PG)
5.0 × 1010
(Alkyl) 
Temp.
Conc.
(mg/mL) 
Response 
unit (ΔRU) 
kd (1/s) ka (1/Ms) KD (M) KA (1/M) ΔH ΔS ΔG 
298 K 0.05 1900 3.98 × 10
-4 
3.03 × 10
4 
1.32 × 10
-8 
7.6 × 10
7 -14.2 -11.7 -10.7
303 K 0.05 1300 4.73 × 10
-4 
2.37 × 10
3 
2.00 × 10
-8 
5.0 × 10
7 
310 K 0.05 780 9.79 × 10
-4 
2.92 × 10
3 
3.35 × 10
-8 
2.9 × 10
7 
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adhered to the VCAM-coated substrate and proportional to the density of VHSPNKK peptides 
(Figure 4C).  In contrast, the KA became maximal when the poly(glycerol) was modified with 1.2 
µM oligopeptides.  Further increase of the degree of substitution of VHSPNKK peptides to 10 
µM rather decreased KA. 
 
Figure 38:  Synthesis of VSHPNKK-poly(glycerol)-g-C18 and evaluation of its function to bind with VCAM-
coated substrate (A.) Chemical reaction scheme to prepare VHSPNKK-poly(glycerol)-g-C18. (B.) SPR analysis of 
the binding of VHSPNKK-poly(glycerol)-g-C18 with the target substrate.  The density of VHSPNKK peptide was 
varied from 0 (●) to 1.2 (▲), 5.0 (▼), and 10 μM (■).  (C.) Quantified maximum response unit and affinity constant 
(KA) for VHSPNKK-poly(glycerol)-g-C18 with varied density of VHSPNKK peptides. 
 
We examined the role of VHSPNKK- poly(glycerol)-g-C18 in guiding cells to a target 
VCAM-coated substrate using SPR.  Interestingly, MSCs coated with VHSPNKK- 
poly(glycerol)-g-C18 displayed significant increase of the association rate and decrease of the 
dissociation rate, as compared with the uncoated MSCs (Figure 5A & 5B).  Specifically, 
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VHSPNKK- poly(glycerol)-g-C18 resulted in the 1.5 fold increase of ka, 70 % decrease of kd, 
and finally more than 3-fold increase of the affinity constant KA (Figure 5C). 
 
Figure 39:  In vitro evaluation of the targeting efficiency of MSCs coated with VHSPNKK-poly(glycerol)-g-C18.  
(a) SPR analysis of the cell dissociation from a target VCAM-coated substrate.  Black circle and red circle represent 
the uncoated MSCs and MSCs associated with VHSPNKK-poly(glycerol)-g-C18, respectively. (b) SPR analysis of 
the cell attachment a target VCAM-coated substrate. Black curve and red curve represent the uncoated MSCs and 
MSCs associated with VHSPNKK-poly(glycerol)-g-C18, respectively.  (c) Quantified analysis of ka and KA for 
uncoated MSCs and MSCs associated with VHSPNKK-poly(glycerol)-g-C18.   
 
In parallel, we examined the adhesion of MSCs to an inflamed endothelial cells using a 
blood vessel-mimicking flow chamber.  The inflamed endothelial cells were prepared by 
exposing the cells to TNF-α to induce over-expression of VCAM.  Both uncoated MSCs and 
MSCs associated with peptide-free poly(glycerol)-g-C18 displayed minimal cell adhesion to the 
inflamed cells (Figure 6A).  In contrast, MSCs associated with VHSPNKK- poly(glycerol)-g-
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C18 actively adhered to the inflamed endothelial cell substrates (Figure 6B).  Ultimately, there 
was a two-fold increase of the number of MSCs adhered to the endothelial cells with use of 
VSPNKK-poly(glycerol)-g-C18 (Figure 6C). 
 
 
Figure 40:  Images of the inflamed endothelial cells exposed to the flow of uncoated MSCs (A.) and MSCs 
associated with VHSPNKK-poly(glycerol)-g-C18 (B.).  (C.) Quantified number of cells adhered to the target 
inflamed endothelial cells. 
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5.3.3.  In vivo evaluation of MSCs modified with poly(glycerol) molecules  in an ischemic 
hindlimb 
Porcine adipose derived MSCs were associated with VSPNKK-poly(glycerol)-g-C18 to 
test whether the cells associated with the cell-guiding molecules can more actively access and 
treat an ischemic tissue via enhanced neovascularization.  MSCs have been actively studied for 
treatment of ischemic tissue, due to the capability of MSCs to produce multiple proangiogenic 
factors and cause revascularzation in wound and tissue defects.  In this study, uncoated MSCs 
and MSCs associated with poly(glycerol) were separately injected into a tail vein of a mouse, 
following the surgery to ligate femoral artery and vein in a mouse hindlimb. 
Cells labeled with an infrared dye were imaged after 12 hours of intravenous cell 
transplantation, a mouse injected with uncoated MSCs displayed minimal difference of the cell 
population in the ischemic site from a control mouse (Figure 7A-1 & 7A-2).  In contrast, mice 
injected with MSCs associated with peptide-free poly(glycerol)-g-C18 and VHSPNKK-
polyglycerl-g-C18 displayed significance increase of the number of transplanted MSCs in the 
ischemic site, as marked with significant increase of the green fluorescence from the transplanted 
cells (Figure 7A-3 & 7A-4).  In addition, the uncoated MSCs were more populated in the lung, as 
compared to MSCs associated with VHSPNKK-polyglycerl-g-C18 (Figure 7B). 
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Figure 41:  In vivo evaluation of the targeting efficiency of MSCs coated with VHSPNKK-poly(glycerol)-g-C18 
and their functions to treat ischemic tissue.  (A) images of the ischemic hindlimb of an untreated mouse (A-1), a 
mouse with transplanted uncoated MSCs (A-2), a mouse with transplanted with MSCs associated with 
poly(glycerol)-g-C18 (A-3), and a mouse with transplanted MSCs associated with VHSPNKK-poly(glycerol)-g-C18 
(A-4).  (B) Images of the lung, kidney, and liver of an untreated mouse (B-1), a mouse transplanted with MSCs 
associated with poly(glycerol)-g-C18 (B-2), and a mouse transplanted with MSCs associated with VHSPNKK-
poly(glycerol)-g-C18 (B-3).   
 
Accordingly, mice transplanted with MSCs associated with VHSPNKK-polyglycerl-g-
C18 displayed more significant enhancement of the recovery of blood perfusion in the ischemic 
hindlimb, characterized with LDPI images (Figure 8A).  Ligation of artery and vein of the 
ischemic hindlimb dramatically decreased the blood perfusion ratio to 45 %, after one day.  
Then, the blood perfusion ratio of the mice transplanted with MSCs associated with VHSPNKK-
poly(glycerol)-g-C18 was increased from 45 % to almost 70 % within 28 days, while the 
untreated mice showed limited increase of the perfusion ratio.  In contrast, mice treated with 
uncoated MSCs and MSCs associated with peptide-free poly(glycerol)-g-C18 showed the 
increase of blood perfusion ratio from 45 % to 58 %. 
(B-1)
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This enhanced recovery of blood perfusion ratio was further related to the number of 
micro-sized blood vessels recreated in the ischemic hindlimb.  According to the cross-section of 
ischemic hindlimb immunostained with antibody to CD31, a marker of endothelial cells, there 
was an increase of the number of CD31-positive blood vessels in mice treated with VHSPNKK-
poly(glycerol)-g-C18, as compared to other conditions (Figure 8B). 
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Figure 42:  (A) LDPI analysis of the recovery of blood perfusion ratio in the ischemic hindlimb of the untreated 
mouse (), the mouse transplanted uncoated MSCs (▲), the mouse transplanted with MSCs associated with 
polyglycerol-g-C18 (●), and the mouse transplanted with MSCs associated with VHSPNKK-polyglycerol-g-C18 
(■).  (B) Immunostained images of the cross-section of an ischemic hindlimb of the untreated mouse (B-1), the 
mouse transplanted uncoated MSCs (B-2), the mouse transplanted with MSCs associated with polyglycerol-g-C18 
(B-3), and the mouse transplanted with MSCs associated with VHSPNKK-polyglycerol-g-C18 (B-4) (*p < 0.05 with 
respect to untreated mouse). 
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5.4 Discussion 
This study created a nano-sized cell-guidance molecule which can associate with 
transplanted cells and guide them to a target site.  This cell-guidance molecule was synthesized 
by chemically conjugating a controlled number of octadecyl groups and VHSPNKK peptides to 
poly(glycerol).  These groups allow the molecule to bind with transplanted cells and the target 
ischemic tissue over-expressing VCAM.  The binding affinity of the poly(glycerol) with 
transplanted cells was modulated with the molecular weight of poly(glycerol), and the targeting 
efficiency towards the target tissue was modulated with the degree of substitution of 
oligopeptides.  The poly(glycerol) with the proper molecular weight, number of octadecyl 
chains, and oligopeptides enhanced the ability of cells to bind with the target ischemic tissue.  
Finally, the MSCs associated with these cell-guidance molecules and transplanted via 
intravascular injection increased the number of newly formed blood vessels and subsequently 
enhanced the recovery of blood perfusion in the ischemic hindlimb. 
First, we suggest that octadecyl chains linked to the poly(glycerol) could associate with 
the lipid molecules of the cell membrane and maintain the association of poly(glycerol) with the 
cells. Interestingly, the binding affinity of the poly(glycerol)-g-C18 to cells could be tuned with 
molecular weight of poly(glycerol), due to the change in thermodynamic properties of the 
physical association.  Specifically, SPR analysis conducted at varied temperatures showed an 
increase in binding affinity with increasing MW of poly(glycerol).  The increase in binding 
affinity resulted from the increase of the Gibbs free energy for association, because of the 
stronger exothermic association.  This approach would be advantageous to elevating binding 
affinity between cells and poly(glycerol), because increase of the degree of substitution of 
octadecyl chains to the poly(glycerol) may damage the cellular membrane and negatively impact 
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cellular viability (21).  Therefore, this approach is distinctive from previous approaches to 
modify cell surface with a carrier through the chemical modification or fusion with cell 
membrane, both of which may inflict cellular viability.  
Further modification of the poly(glycerol)-g-C18 with VHSPNKK peptides increased the 
binding affinity of the alkyl-substituted poly(glycerol) with VCAM-coated substrates, which are 
the model target of endothelium damaged by inflammation.  The increase of the number of 
poly(glycerol) bound to the VCAM-coated substrates was proportional to the concentration of 
the poly(glycerol) and is attributed to the larger number of bonds formed between the 
poly(glycerol) and VCAM molecules on the substrate.  However, the maximal association 
constant at an intermediate concentration, which could result from competitive interactions at the 
high concentration of poly(glycerol).  
The in vitro evaluation of the capability of VHSPNKK-polglycerol-g-C18 to guiding the 
cells to the target VCAM coated substrate confirms that the poly(glycerol) associated with cells 
significantly enhances the cellular ability to probe and anchor to the target site, similar to 
leukocytes mobilized to the injured endothelium (22).  The SPR analysis addresses that the 
poly(glycerol) associated with cells significantly changed kinetic properties of cell adhesion to 
the VCAM-overexpressing endothelial cells, as indicated by the increase of the association rate 
and the decrease of dissociation rate.  Previous studies reported that cells associated with nano-
carriers modified with peptides or antibodies binding with selectin or ICAM exhibit the 
enhanced cell adhesion to a target substrate (11-12).  However, no study demonstrated a success 
to guide the cells to a more physiologically relevant target substrate, such as the substrate 
covered with inflamed endothelial cells.  
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Finally, this study demonstrated that the nano-sized guidance molecule is useful for 
guiding the MSCs systemically transplanted to the target ischemic area and improving the 
recovery of blood perfusion in the ischemic hindlimb.  The cells coated with poly(glycerol)-g-
C18 and VHSPNKK-poly(glycerol)-g-C18 could be mobilized to the target ischemic hindlimb.  
However, we propose that the cells coated with VHSPNKK-poly(glycerol)-g-C18 could stay in 
the ischemic tissue more sustainably and produce multiple angiogenic growth factors more 
actively than conditions without the delivery of therapeutic cells, as shown with the larger blood 
perfusion ratio and number of newly formed blood vessels.  However, for the more precise 
interpretation, it is necessary to examine MSCs mobilized to the target site at a later time-point, 
since the in vivo cell imaging was conducted 16 hours after cellular injection, and also pro-
angiogenic activities, characterized with concentration of VEGF and bFGF in the ischemic 
hindlimb.  Furthermore, in future studies the investigation of spatially patterned poly(glycerol) 
may provide an improvement over poly(glycerol)-g-C18 by minimizing the interaction of alkyl 
chains with non-therapeutic cells. 
 
5.5  Conclusions 
 Overall, this study demonstrates a novel cell-guidance molecule which can associate with 
cells and further guide them to target sites following the systemic transplantation.  In vitro 
studies addressed that octadecyl chains linked to the higher molecular weight poly(glycerol) 
associated with cells in a thermodynamically favorable manner.  The VHSPNKK peptide linked 
to the poly(glycerol)-g-C18 successfully guided cells to the target endothelial cells due to the 
increase of the association rate and decrease of the dissociation rate.  Therefore, stem cells 
coated with VHSPNKK-poly(glycerol)-g-C18 transplanted via systemic intravascular injection 
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could significantly enhance recovery of blood perfusion in the ischemic hindlimb, as compared a 
lack of treatment.  We suggest that the nano-sized cell-guidance molecule created in this study 
should be highly useful to guiding systemically transplanted therapeutic cells to a target tissue 
and improving quality of cell therapies. 
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